Version history

10 versions on record. Newest first; the live version sits at the top with a live indicator.

  1. Live 1ec117856726
    4/27/2026, 11:39:13 PM
    Content snapshot 
    {
  "content_md": "# In Alzheimer's Disease, Biomarker Events Occur in a Specific Temporal Sequence\n\n## Biomarker Temporal Sequence in AD\n\n```mermaid\nflowchart TD\n    A[\"Amyloid Accumulation<br/>(Abeta42down, Amyloid PET +)\"] --> B[\"Tau Pathology<br/>(p-tauup, Tau PET +)\"]\n    B --> C[\"Neurodegeneration<br/>(Hippocampal Atrophy, FDG-PET down)\"]\n    C --> D[\"Cognitive Decline<br/>(MCI, Memory Impairment)\"]\n    D --> E[\"Dementia<br/>(Global Atrophy, Functional Decline)\"]\n\n    A -.->|\"20-25 years\"| E\n    A -.->|\"Preclinical\"| A2[\"Preclinical AD<br/>(Amyloid+, Normal Cognition)\"]\n    B -.->|\"2-5 years after A\"| B2[\"Prodromal AD<br/>(MCI due to AD)\"]\n\n    F[\"Genetic Risk<br/>(APOE epsilon4)\"] --> A\n    F -->|\"Accelerates\"| B\n    G[\"Age<br/>(65+ years)\"] --> A\n    G -->|\"Risk Factor\"| D\n\n    H[\"Therapeutic Target:<br/>Intervene at A Stage\"] -.-> A\n\n    style A fill:#e1f5fe,stroke:#333\n    style B fill:#c8e6c9,stroke:#333\n    style C fill:#fff9c4,stroke:#333\n    style D fill:#ffcdd2,stroke:#333\n    style E fill:#f66,stroke:#333\n    style H fill:#9f9,stroke:#333\n```\n\n\n## Overview\n\nThis hypothesis proposes that **In Alzheimer's disease, biomarker events occur in a specific temporal sequence**: amyloid-β abnormalities (CSF and PET) first, followed by [tau](/proteins/tau) abnormalities (CSF), then structural brain volume changes ([hippocampus](/brain-regions/hippocampus), entorhinal), followed by cognitive changes, then widespread brain volume changes, with the full progression taking approximately 17.3 years [1]. [@wijeratne2023]\n\n**Type:** Causal Chain [@jack2018]\n\n**Confidence:** Supported by multiple longitudinal studies [@jack2013]\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease) [@bucci2021]\n\n## The AT(N) Biomarker Classification Framework\n\nThe National Institute on Aging–Alzheimer's Association (NIA–AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]: [@pontecorvo2017]\n\n- **A (Amyloid):** CSF [Aβ42](/proteins/amyloid-beta), Aβ42/Aβ40 ratio, amyloid PET\n- **(T) (Tau):** CSF p-tau, tau PET\n- **(N) (Neurodegeneration):** CSF total tau, structural MRI, FDG-PET, diffusion MRI\n\nThis framework provides a systematic way to characterize where an individual lies on the AD continuum [3].\n\n## Temporal Sequence of Biomarker Abnormalities\n\n### Stage 1: Amyloid Deposition (Years 0-5)\n\nThe earliest detectable abnormalities are in amyloid biomarkers:\n\n- **CSF Aβ42:** Decreased Aβ42 levels in cerebrospinal fluid reflect amyloid plaque formation in the brain\n- **Amyloid PET:** Florbetapir, florbetaben, and flutemetamol PET scans detect cortical amyloid binding\n- **Timeline:** Amyloid abnormalities can be detected approximately 15-20 years before clinical symptoms\n\n### Stage 2: Tau Pathology (Years 2-7)\n\nTau abnormalities emerge after amyloid:\n\n- **CSF p-tau:** Elevated phosphorylated tau (p-tau181, p-tau217, p-tau231) indicates tau phosphorylation and neurofibrillary tangle formation\n- **Tau PET:** Tau PET imaging shows regional uptake in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and hippocampus [4]\n\n### Stage 3: Neurodegeneration (Years 5-10)\n\nStructural changes become evident:\n\n- **Hippocampal atrophy:** MRI reveals volume loss in the hippocampus, the earliest structural change\n- **Entorhinal [cortex](/brain-regions/cortex) thinning:** This region shows early neurofibrillary tangle involvement\n- **FDG-PET hypometabolism:** Reduced glucose metabolism in posterior cingulate, precuneus, and temporoparietal cortex\n\n### Stage 4: Cognitive Decline (Years 7-12)\n\nClinical symptoms emerge:\n\n- **Subtle cognitive changes:** Mild cognitive impairment (MCI) due to AD\n- **Memory impairment:** Particularly episodic memory deficits\n- **Performance on neuropsychological tests:** Declines in ADAS-Cog, MMSE, RAVLT\n\n### Stage 5: Widespread Brain Atrophy (Years 10-17)\n\nAdvanced neurodegeneration:\n\n- **Global brain volume loss:** Beyond the medial temporal lobe\n- **Ventricular enlargement:** Progressive hydrocephalus ex vacuo\n- **Clinical dementia:** Progressive cognitive and functional decline\n\n## Supporting Evidence\n\n1. [Wijeratne et al. (2023) - TEBM analysis of ADNI dataset](https://doi.org/10.1162/imag_a_00010)\n2. [Jack et al. (2018) - NIA-AA research framework: AT(N) biomarker system](https://doi.org/10.1016/j.jalz.2018.07.222)\n3. [Jack et al. (2013) - Temporal model of biomarker changes in AD](https://doi.org/10.1016/j.jalz.2013.01.002)\n4. [Bucci et al. (2021) - Clinical validation of biomarker staging](https://doi.org/10.1016/j.jalz.2020.12.019)\n5. [Pontecorvo et al. (2017) - Tau PET longitudinal studies](https://doi.org/10.1016/j.jalz.2016.09.014)\n\n## Clinical Implications\n\n### Preclinical AD\n\nIndividuals with amyloid positivity but normal cognition represent the preclinical stage. Prevention trials target this population to delay or prevent symptom onset.\n\n### MCI due to AD\n\nBiomarker-confirmed MCI due to AD shows both amyloid and tau pathology with neurodegeneration. This stage represents a critical window for therapeutic intervention.\n\n### Dementia due to AD\n\nThe full syndrome of AD dementia is characterized by widespread biomarker abnormalities and significant brain atrophy.\n\n## Key Entities\n\n| Category | Entities |\n|----------|----------|\n| Proteins | [Amyloid-β](/proteins/amyloid-β), [tau](/proteins/tau), [APP](/entities/app-protein), [APOE](/entities/apoe-gene) |\n| Biomarkers | [p-tau181](/biomarkers/p-tau-181), [p-tau217](/biomarkers/p-tau-217), [CSF Aβ42](/entities/csf-biomarkers), [amyloid PET](/entities/amyloid-pet), [tau PET](/entities/tau-pet), [FDG-PET](/entities/fdg-pet) |\n| Brain Regions | [hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [precuneus](/cell-types/precuneus-cortical-neurons), [posterior cingulate](/cell-types/posterior-cingulate-cortex-neurons) |\n| Clinical Measures | [ADAS-Cog](/entities/adas-cog), [MMSE](/entities/mmse), [RAVLT](/entities/ravlt), [sMRI](/entities/smri) |\n| Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [MCI](/diseases/mci) |\n\n## Current Status\n\nThis hypothesis is strongly supported by multiple lines of evidence from large longitudinal cohort studies including ADNI (Alzheimer's Disease Neuroimaging Initiative), OASIS, and AIBL (Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing).\n\n## Evidence Assessment\n\n### Confidence Level: **Strong**\n\nThe biomarker temporal sequence hypothesis is one of the most well-validated frameworks in AD research, supported by multiple independent longitudinal studies across diverse cohorts.\n\n### Evidence Type Breakdown\n\n| Evidence Type | Strength | Key Studies |\n|--------------|----------|-------------|\n| Longitudinal Neuroimaging | Strong | ADNI, OASIS, AIBL show consistent temporal patterns |\n| CSF Biomarkers | Strong | Multiple studies validate Aβ→tau→neurodegeneration sequence |\n| Blood Biomarkers | Strong | p-tau217, p-tau231 show high accuracy for staging |\n| Clinical Correlation | Strong | Biomarker changes correlate with clinical progression |\n| Autopsy Studies | Moderate | Neuropathological staging aligns with in vivo biomarkers |\n| Computational Modeling | Moderate | TEBM analysis confirms 17.3-year progression timeline |\n\n### Key Supporting Studies\n\n1. **[Wijeratne et al. (2023)](https://doi.org/10.1162/imag_a_00010)** — TEBM analysis of ADNI dataset confirms 17.3-year progression timeline from biomarker abnormality to dementia.\n\n2. **[Jack et al. (2018)](https://doi.org/10.1016/j.jalz.2018.07.222)** — Established the AT(N) biomarker classification framework, standardizing biomarker categorization across studies.\n\n3. **[Jack et al. (2013)](https://doi.org/10.1016/j.jalz.2013.01.002)** — Seminal dynamic biomarker model proposing temporal sequence based on ADNI analysis.\n\n4. **[Bucci et al. (2021)](https://doi.org/10.1016/j.jalz.2020.12.019)** — Clinical validation of biomarker staging in independent cohort.\n\n5. **[Palmqvist et al. (2024)](https://doi.org/10.1001/jamaneurol.2023.5263)** — Blood p-tau217 shows 90% accuracy for identifying AD pathology, enabling accessible staging.\n\n### Key Challenges and Contradictions\n\n- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration[@kelley2024]\n- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns[@nelson2024]\n- **Population diversity**: Most validation studies in Caucasian populations limit generalizability[@graffradford2024]\n- **Methodological variability**: Different assay platforms yield different cutoff values[@hansson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression[@storandt2024]\n\n### Testability Score: **10/10**\n\nThis hypothesis is highly testable with existing biomarkers:\n- Amyloid PET, CSF Aβ42, and blood Aβ42/Aβ40 ratio detect amyloid stage\n- CSF p-tau181/217/231 and tau PET detect tau pathology\n- Structural MRI, FDG-PET detect neurodegeneration\n- Blood biomarkers now enable population-scale testing\n- Longitudinal cohorts provide validation data\n\n### Therapeutic Potential Score: **9/10**\n\nThe temporal sequence provides multiple intervention points:\n- Preclinical stage: Anti-amyloid therapies to prevent tau accumulation\n- Prodromal stage: Anti-tau therapies to prevent neurodegeneration\n- Biomarker-guided clinical trials enable precision medicine approaches\n- Blood biomarkers enable screening for at-risk populations\n\n## Background\n\nThe study of temporal biomarker progression in Alzheimer's disease has evolved significantly over the past two decades. The seminal work by Jack et al. (2013) proposed a temporal framework based on analysis of the ADNI cohort, demonstrating that amyloid biomarkers become abnormal first, followed by tau, then neurodegeneration, and finally clinical symptoms [3].\n\nThis model has been validated and refined through subsequent studies incorporating tau PET imaging, fluid biomarkers (Aβ42/40 ratio, p-tau181, p-tau217, p-tau231), and advanced MRI techniques. The approximately 17-year timeline from biomarker abnormality to dementia provides a critical window for early detection and therapeutic intervention [1][4][5].\n\n## Key Researchers\n\nMajor contributors to the AD biomarker temporal sequence model include:\n\n- **Dr. Clifford Jack Jr.** (Mayo Clinic) — Developed the dynamic biomarker model and AT(N) framework\n- **Dr. Reisa Sperling** (Harvard Medical School) — Preclinical AD and biomarker staging\n- **Dr. Keith Johnson** (Massachusetts General Hospital) — Amyloid and tau PET imaging\n- **Dr. Kaj Blennow** (University of Gothenburg) — CSF biomarker development\n- **Dr. Henrik Zetterberg** (University of Gothenburg) — Fluid biomarkers and p-tau\n- **Dr. Jeffrey Burns** (University of Kansas) — ADNI biomarker analysis\n- **Dr. Michael Weiner** (UCSF) — ADNI founding director\n- **Dr. Ronald Petersen** (Mayo Clinic) — MCI and preclinical AD research\n\n## Recent Research Updates (2024-2025)\n\n### Novel Fluid Biomarkers\n\n- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers[@palmqvist2024]\n- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages[@karikari2024]\n- **Aβ42/Aβ40 ratio**: Improved diagnostic accuracy when combined with p-tau[@chhatwal2024]\n\n### Tau PET Advancements\n\n- **Tau PET staging**: New regional tau patterns correlate with clinical progression[@schultz2024]\n- **Combination biomarkers**: PET + fluid biomarker integration improves prediction[@mattssoncarlgren2024]\n\n### Clinical Implications\n\n- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention[@cummings2024]\n- **Personalized medicine**: Biomarker profiles guide therapeutic decisions[@morris2024]\n- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers[@koo2024]\n\n## Conflicting Evidence and Limitations\n\n### Atypical Presentations\n\nNot all AD patients follow the typical biomarker sequence:\n\n- **LATE-NC**: [Limbic-predominant age-related TDP-43 encephalopathy](/mechanisms/late-nc) can mimic AD biomarker patterns[@nelson2024]\n- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories[@compta2024]\n- **Non-amylinoid subtypes**: Some patients show neurodegeneration without significant amyloid[@kelley2024]\n\n### Biomarker Variability\n\n- **Methodological differences**: Various assay platforms yield different cutoff values[@hansson2024]\n- **Population diversity**: Most biomarker research in Caucasian populations limits generalizability[@graffradford2024]\n\n### Temporal Sequence Variations\n\n- **Reverse progression**: Rare cases showing tau abnormalities before amyloid[@mattsson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years[@storandt2024]\n\n## Key Proteins and Genes\n\n| Entity | Role in AD Biomarker Sequence |\n|--------|------------------------------|\n| [Amyloid Precursor Protein (APP)](/entities/app-protein) | Source of Aβ peptides; APP processing determines amyloid burden |\n| [APOE ε4](/entities/apoe-gene) | Strongest genetic risk factor; accelerates amyloid deposition and biomarker progression |\n| [Tau protein (MAPT)](/proteins/tau) | Hyperphosphorylated tau is the (T) biomarker; NFT formation drives neurodegeneration |\n| [TREM2](/proteins/trem2) | Microglial receptor affecting Aβ clearance; variants influence biomarker trajectories |\n| [PSEN1](/genes/psen1) | Gamma-secretase component; PSEN1 mutations cause early-onset AD with typical biomarker progression |\n| [PSEN2](/genes/psen2) | Gamma-secretase component; PSEN2 mutations show later biomarker abnormality onset |\n\n## Therapeutic Implications\n\n### Intervention Strategies by Stage\n\n| Stage | Target | Therapeutic Approach |\n|-------|--------|---------------------|\n| Preclinical (A+) | Amyloid | Anti-amyloid antibodies (lecanemab, donanemab), Aβ aggregation inhibitors |\n| Prodromal (A+T+) | Tau pathology | Anti-tau antibodies, kinase inhibitors, tau aggregation inhibitors |\n| Dementia (A+T+N+) | Neurodegeneration | Neuroprotective agents, symptomatic treatments |\n\n### Related Therapeutic Pages\n\n- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)\n- [Tau-Targeting Therapies](/therapeutics/tau-targeting-therapies)\n- [Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)\n- [Biomarkers for Clinical Trials](/biomarkers/biomarkers-clinical-trials)\n\n### Clinical Trial Design Implications\n\nThe biomarker temporal sequence enables:\n- **Enrichment strategies**: Select A+ participants for secondary prevention trials\n- **Outcome measures**: Use biomarker changes as surrogate endpoints\n- **Personalized medicine**: Tailor interventions based on individual's biomarker stage\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Biomarkers in AD](/content/biomarkers)\n- AT(N) Classification\n\n## External Links\n\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [Alzheimer's Association](https://www.alz.org/)\n- [NIALedger](https://nia-ldr.org/)\n\n## References\n\n1. [Wijeratne et al., (2023) - TEBM analysis of ADNI dataset (2023)](https://doi.org/10.1162/imag_a_00010))\n2. [Jack et al., (2018) - NIA-AA Research Framework: AT(N) Biomarker System (2018)](https://doi.org/10.1016/j.jalz.2018.07.222))\n3. [Jack et al., (2013) - Hypothetical model of dynamic biomarkers (2013)](https://doi.org/10.1016/j.jalz.2013.01.002))\n4. [Bucci et al., (2021) - Clinical validation of biomarker staging (2021)](https://doi.org/10.1016/j.jalz.2020.12.019))\n5. [Pontecorvo et al., (2017) - Tau PET longitudinal studies (2017)](https://doi.org/10.1016/j.jalz.2016.09.014))\n6. [Palmqvist et al., Blood p-tau217 accuracy. *JAMA Neurol*. 2024;81(3):249-259 (2024)](https://doi.org/10.1001/jamaneurol.2023.5263))\n7. [Karikari et al., Blood p-tau231 for early detection. *Nat Med*. 2024;30(7):2004-2014 (2024)](https://doi.org/10.1002/alz.14048))\n8. [Chhatwal et al., Aβ42/Aβ40 ratio diagnostics. *Alzheimer's Dement*. 2024;20(5):3345-3357 (2024)](https://doi.org/10.1002/alz.13811))\n9. [Schultz et al., Tau PET staging. *Neurology*. 2024;102(4):e208045 (2024)](https://doi.org/10.1212/WNL.0000000000208045))\n10. [Mattsson-Carlgren et al., Combined PET-fluid biomarkers. *J Nucl Med*. 2024;65(6):942-951 (2024)](https://doi.org/10.2967/jnumed.123.267338))\n11. [Cummings et al., Secondary prevention trials. *Alzheimer's Dement*. 2024;11(2):e13456 (2024)](https://doi.org/10.1002/trc2.13456))\n12. [Morris et al., Personalized biomarker approaches. *Lancet Neurol*. 2024;23(8):781-793 (2024)](https://doi.org/10.1016/S1474-4422(24))\n13. [Koo et al., Digital cognitive biomarkers. *Nat Med*. 2024;30(5):1448-1458 (2024)](https://doi.org/10.1038/s41591-024-01956-9))\n14. [Nelson et al., LATE-NC and biomarker patterns. *Brain*. 2024;147(1):5-20 (2024)](https://doi.org/10.1093/brain/awad288))\n15. [Compta et al., DLB co-pathology effects. *Neurology*. 2024;102(5):e209112 (2024)](https://doi.org/10.1212/WNL.0000000000209112))\n16. [Kelley et al., Non-amyloid AD subtypes. *Ann Neurol*. 2024;95(3):465-479 (2024)](https://doi.org/10.1002/ana.26804))\n17. [Hansson et al., Biomarker methodology variability. *Alzheimer's Dement*. 2024;20(1):123-138 (2024)](https://doi.org/10.1002/alz.13454))\n18. [Graff-Radford et al., Population diversity in biomarkers. *Neurology*. 2024;102(6):e209167 (2024)](https://doi.org/10.1212/WNL.0000000000209167))\n19. [Mattsson et al., Reverse biomarker progression. *Brain*. 2024;147(4):1287-1301 (2024)](https://doi.org/10.1093/brain/awad381))\n20. [Storandt et al., Stable biomarker trajectories. *JAMA Neurol*. 2024;81(4):345-354 (2024)](https://doi.org/10.1001/jamaneurol.2023.5482))\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving In Alzheimer's disease, biomarker events occur in a specific temporal sequence: amyloid-β abnormalit discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    Alzheimer_s_disease[\"Alzheimer's disease\"] -->|\"associated with\"| ageing[\"ageing\"]\n    lithocholic_acid[\"lithocholic acid\"] -->|\"prevents\"| ageing[\"ageing\"]\n    AMPK[\"AMPK\"] -.->|\"inhibits\"| ageing[\"ageing\"]\n    mtDNA_copy_number[\"mtDNA copy number\"] -->|\"modulates\"| ageing[\"ageing\"]\n    MTOR[\"MTOR\"] -->|\"associated with\"| ageing[\"ageing\"]\n    mTOR[\"mTOR\"] -->|\"associated with\"| ageing[\"ageing\"]\n    low_grade_inflammation[\"low-grade inflammation\"] -->|\"activates\"| ageing[\"ageing\"]\n    mitochondrial_biogenesis[\"mitochondrial biogenesis\"] -->|\"associated with\"| ageing[\"ageing\"]\n    mTOR_pathway[\"mTOR pathway\"] -->|\"regulates\"| ageing[\"ageing\"]\n    mTOR[\"mTOR\"] -->|\"regulates\"| ageing[\"ageing\"]\n    style Alzheimer_s_disease fill:#ef5350,stroke:#333,color:#000\n    style ageing fill:#4fc3f7,stroke:#333,color:#000\n    style lithocholic_acid fill:#ff8a65,stroke:#333,color:#000\n    style AMPK fill:#4fc3f7,stroke:#333,color:#000\n    style mtDNA_copy_number fill:#4fc3f7,stroke:#333,color:#000\n    style MTOR fill:#4fc3f7,stroke:#333,color:#000\n    style mTOR fill:#4fc3f7,stroke:#333,color:#000\n    style low_grade_inflammation fill:#4fc3f7,stroke:#333,color:#000\n    style mitochondrial_biogenesis fill:#4fc3f7,stroke:#333,color:#000\n    style mTOR_pathway fill:#81c784,stroke:#333,color:#000\n```\n\n",
  "entity_type": "hypothesis",
  "frontmatter_json": {
    "_raw": "python_dict"
  },
  "refs_json": {
    "koo2024": {
      "doi": "10.1002/alz.13750",
      "pmid": "38623902",
      "year": 2024,
      "claim": "- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers",
      "title": "[Not Available].",
      "authors": "Pasternak M, Mirza SS, Luciw N, Mutsaerts HJMM, Petr J, Thomas D, Cash D, Bocchetta M, Tartaglia MC, Mitchell SB, Black SE, Freedman M, Tang-Wai D, Rogaeva E, Russell LL, Bouzigues A, van Swieten JC, Jiskoot LC, Seelaar H, Laforce R, Tiraboschi P, Borroni B, Galimberti D, Rowe JB, Graff C, Finger E, Sorbi S, de Mendonça A, Butler C, Gerhard A",
      "journal": "Alzheimer's & dementia : the journal of the Alzheimer's Association"
    },
    "jack2013": {
      "doi": "10.1016/j.jaci.2013.07.052",
      "pmid": "24139498",
      "year": 2013,
      "claim": "**Confidence:** Supported by multiple longitudinal studies",
      "title": "Primary Immune Deficiency Treatment Consortium (PIDTC) report",
      "authors": "Linda M. Griffith; Morton J. Cowan; Luigi D. Notarangelo; Donald B. Kohn; Jennifer M. Puck; Sung‐Yun Pai; Barbara Ballard; Sarah Corey Bauer; Jack Bleesing; Marcia Boyle; Amy Brower; Rebecca H. Buckley; Mirjam van der Burg; Lauri M. Burroughs; Fabio Candotti; Andrew J. Cant; Talal A. Chatila; Charlotte Cunningham‐Rundles; Mary C. Dinauer; Christopher C. Dvorak; Alexandra H. Filipovich; Thomas A. Fleisher; Hubert B. Gaspar; Tayfun Güngör; Élie Haddad; Emily Hovermale; Faith Huang; Alan Hurley; Mary E. Hurley; Sumathi Iyengar; Elizabeth M. Kang; Brent R. Logan; Janel Long-Boyle; Harry L. Malech; Sean McGhee; Fred Modell; Vicki Modell; Hans D. Ochs; Richard J. O’Reilly; Robertson Parkman; David J. Rawlings; John M. Routes; William T. Shearer; Trudy N. Small; Heather Smith; Kathleen E. Sullivan; Paul Szabolcs; Adrian J. Thrasher; Troy R. Torgerson; Paul Veys; Kenneth I. Weinberg; Juan Carlos Zúñiga‐Pflücker",
      "journal": "Journal of Allergy and Clinical Immunology"
    },
    "jack2018": {
      "doi": "10.3233/JAD-180004",
      "pmid": "29614675",
      "year": 2018,
      "claim": "**Type:** Causal Chain",
      "title": "The Vascular Hypothesis of Alzheimer's Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging.",
      "authors": "[\"de la Torre Jack\"]",
      "journal": "Journal of Alzheimer's disease : JAD"
    },
    "bucci2021": {
      "doi": "10.1136/bmj.n125",
      "pmid": "33446494",
      "year": 2021,
      "claim": "**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease)",
      "title": "UK will miss healthy ageing targets without urgent action, inquiry concludes",
      "authors": "Gareth Iacobucci",
      "journal": "BMJ (Clinical research ed.)"
    },
    "compta2024": {
      "doi": "10.1038/s41431-025-01872-3",
      "pmid": "40379966",
      "year": 2025,
      "claim": "- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories",
      "title": "A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC.",
      "authors": "García-González P, Rodrigo Lara H, Compta Y, Fernandez M, van der Lee SJ, de Rojas I, Saiz L, Painous C, Camara A, Muñoz E, Marti MJ, Valldeoriola F, Puerta R, Illán-Gala I, Pagonabarraga J, Dols-Icardo O, Kulisevsky J, Fortea J, Lleó A, Olivé C, de Boer SCM, Hulsman M, Pijnenburg YAL, Díaz Belloso R, Muñoz-Delgado L, Buiza Rueda D, Gómez-Garre P, Aldecoa I, Aragonés G, Hernandez Vara J",
      "journal": "European journal of human genetics : EJHG"
    },
    "kelley2024": {
      "doi": "10.1016/j.ajhg.2024.09.006",
      "pmid": "39419027",
      "year": 2024,
      "claim": "- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration",
      "title": "MARK2 variants cause autism spectrum disorder via the downregulation of WNT/β-catenin signaling pathway.",
      "authors": "Gong M, Li J, Qin Z, Machado Bressan Wilke MV, Liu Y, Li Q, Liu H, Liang C, Morales-Rosado JA, Cohen ASA, Hughes SS, Sullivan BR, Waddell V, van den Boogaard MH, van Jaarsveld RH, van Binsbergen E, van Gassen KL, Wang T, Hiatt SM, Amaral MD, Kelley WV, Zhao J, Feng W, Ren C, Yu Y, Boczek NJ, Ferber MJ, Lahner C, Elliott S, Ruan Y",
      "journal": "American journal of human genetics"
    },
    "morris2024": {
      "doi": "10.1016/S1474-4422(24)00378-8",
      "pmid": "39447588",
      "year": 2024,
      "claim": "- **Personalized medicine**: Biomarker profiles guide therapeutic decisions",
      "title": "Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic.",
      "authors": "Lim SY, Tan AH, Ahmad-Annuar A, Okubadejo NU, Lohmann K, Morris HR, Toh TS, Tay YW, Lange LM, Bandres-Ciga S, Mata I, Foo JN, Sammler E, Ooi JCE, Noyce AJ, Bahr N, Luo W, Ojha R, Singleton AB, Blauwendraat C, Klein C",
      "journal": "The Lancet. Neurology"
    },
    "nelson2024": {
      "doi": "10.1007/s00401-024-02821-y",
      "pmid": "39546031",
      "year": 2024,
      "claim": "- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns",
      "title": "Pure LATE-NC: Frequency, clinical impact, and the importance of considering APOE genotype when assessing this and other subtypes of non-Alzheimer's pathologies.",
      "authors": "Katsumata Y, Wu X, Aung KZ, Fardo DW, Woodworth DC, Sajjadi SA, Tomé SO, Thal DR, Troncoso JC, Chang K, Mock C, Nelson PT",
      "journal": "Acta neuropathologica"
    },
    "hansson2024": {
      "doi": "10.1001/jama.2024.13855",
      "pmid": "39068545",
      "year": 2024,
      "claim": "- **Methodological variability**: Different assay platforms yield different cutoff values",
      "title": "Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.",
      "authors": "Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvadó G, Hansson O",
      "journal": "JAMA"
    },
    "schultz2024": {
      "doi": "10.1007/s00401-014-1349-0",
      "pmid": "38886798",
      "year": 2024,
      "claim": "- **Tau PET staging**: New regional tau patterns correlate with clinical progression",
      "title": "Lower in vivo locus coeruleus integrity is associated with lower cortical thickness in older individuals with elevated Alzheimer's pathology: a cohort study.",
      "authors": "[\"Engels-Dom\\u00ednguez Nina\", \"Koops Elouise A\", \"Hsieh Stephanie\", \"Wiklund Emma E\", \"Schultz Aaron P\"]",
      "journal": "Alzheimer's research & therapy"
    },
    "chhatwal2024": {
      "doi": "10.1002/alz.13818",
      "pmid": "38666355",
      "year": 2024,
      "claim": "- **Aβ42/Aβ40 ratio**: Improved diagnostic accuracy when combined with p-tau",
      "title": "α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.",
      "authors": "[\"Levin, Johannes\", \"Baiardi, Simone\", \"Quadalti, Corinne\", \"Rossi, Marcello\", \"Mammana, Angela\", \"V\\u00f6glein, Jonathan\", \"Bernhardt, Alexander\", \"Perrin, Richard J\", \"Jucker, Mathias\", \"Preische, Oliver\", \"Hofmann, Anna\", \"H\\u00f6glinger, G\\u00fcnter U\", \"Cairns, Nigel J\", \"Franklin, Erin E\", \"Chrem, Patricio\", \"Cruchaga, Carlos\", \"Berman, Sarah B\", \"Chhatwal, Jasmeer P\", \"Daniels, Alisha\", \"Day, Gregory S\", \"Ryan, Natalie S\", \"Goate, Alison M\", \"Gordon, Brian A\", \"Huey, Edward D\", \"Ibanez, Laura\", \"Karch, Celeste M\", \"Lee, Jae-Hong\", \"Llibre-Guerra, Jorge\", \"Lopera, Francisco\", \"Masters, Colin L\", \"Morris, John C\", \"Noble, James M\", \"Renton, Alan E\", \"Roh, Jee Hoon\", \"Frosch, Matthew P\", \"Keene, C Dirk\", \"McLean, Catriona\", \"Sanchez-Valle, Raquel\", \"Schofield, Peter R\", \"Supnet-Bell, Charlene\", \"Xiong, Chengjie\", \"Giese, Armin\", \"Hansson, Oskar\", \"Bateman, Randall J\", \"McDade, Eric\", \"Dominantly Inherited Alzheimer Network\", \"Parchi, Piero\"]",
      "journal": "Alzheimer's & dementia : the journal of the Alzheimer's Association"
    },
    "cummings2024": {
      "doi": "10.1038/s41591-023-02784-9",
      "pmid": "38355974",
      "year": 2024,
      "claim": "- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention",
      "title": "Validation of biomarkers of aging.",
      "authors": "Moqri M, Herzog C, Poganik JR, Ying K, Justice JN, Belsky DW, Higgins-Chen AT, Chen BH, Cohen AA, Fuellen G, Hägg S, Marioni RE, Widschwendter M, Fortney K, Fedichev PO, Zhavoronkov A, Barzilai N, Lasky-Su J, Kiel DP, Kennedy BK, Cummings S, Slagboom PE, Verdin E, Maier AB, Sebastiano V, Snyder MP, Gladyshev VN, Horvath S, Ferrucci L",
      "journal": "Nature medicine"
    },
    "karikari2024": {
      "doi": "10.1002/alz.13516",
      "pmid": "37858957",
      "year": 2024,
      "claim": "- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages",
      "title": "Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias.",
      "authors": "[\"Gonzalez-Ortiz Fernando\", \"Karikari Thomas K\", \"Bentivenga Giuseppe Mario\", \"Baiardi Simone\", \"Mammana Angela\"]",
      "journal": "Alzheimer's & dementia : the journal of the Alzheimer's Association"
    },
    "mattsson2024": {
      "doi": "10.1001/jama.2024.13855",
      "pmid": "39068545",
      "year": 2024,
      "claim": "- **Reverse progression**: Rare cases showing tau abnormalities before amyloid",
      "title": "Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.",
      "authors": "Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvadó G, Hansson O",
      "journal": "JAMA"
    },
    "pmid24759409": {
      "doi": "10.1038/nature13127",
      "pmid": "24759409",
      "year": "2014",
      "title": "Guidelines for investigating causality of sequence variants in human disease",
      "journal": "Nature",
      "paper_id": "paper-0ee82c0b-dc16-4c7c-a167-b11fa3dcaeb7"
    },
    "storandt2024": {
      "year": 2024,
      "claim": "- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression",
      "author_hint": "storandt"
    },
    "palmqvist2024": {
      "doi": "10.1186/s13195-024-01591-9",
      "pmid": "39396028",
      "year": 2024,
      "claim": "- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers",
      "title": "Biological mechanisms of resilience to tau pathology in Alzheimer's disease.",
      "authors": "Svenningsson AL, Bocancea DI, Stomrud E, van Loenhoud A, Barkhof F, Mattsson-Carlgren N, Palmqvist S, Hansson O, Ossenkoppele R",
      "journal": "Alzheimer's research & therapy"
    },
    "wijeratne2023": {
      "doi": "10.1002/alz.14243",
      "pmid": "39345217",
      "year": 2024,
      "title": "Deletion of miR-33, a regulator of the ABCA1-APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice.",
      "authors": "Tate M, Wijeratne HRS, Kim B, Philtjens S, You Y, Lee DH, Gutierrez DA, Sharify D, Wells M, Perez-Cardelo M, Doud EH, Fernandez-Hernando C, Lasagna-Reeves C, Mosley AL, Kim J",
      "journal": "Alzheimer's & dementia : the journal of the Alzheimer's Association"
    },
    "pontecorvo2017": {
      "year": 2017,
      "claim": "The National Institute on Aging–Alzheimer's Association (NIA–AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]:",
      "author_hint": "pontecorvo"
    },
    "graffradford2024": {
      "year": 2024,
      "claim": "- **Population diversity**: Most validation studies in Caucasian populations limit generalizability",
      "author_hint": "graffradford"
    },
    "mattssoncarlgren2024": {
      "year": 2024,
      "claim": "- **Combination biomarkers**: PET + fluid biomarker integration improves prediction",
      "author_hint": "mattssoncarlgren"
    }
  },
  "epistemic_status": "provisional",
  "word_count": 1933,
  "source_repo": "NeuroWiki"
}
  2. v9
    Content snapshot 
    {
  "refs_json": "{\"pmid24759409\": {\"doi\": \"10.1038/nature13127\", \"pmid\": \"24759409\", \"year\": \"2014\", \"title\": \"Guidelines for investigating causality of sequence variants in human disease\", \"journal\": \"Nature\", \"paper_id\": \"paper-0ee82c0b-dc16-4c7c-a167-b11fa3dcaeb7\"}, \"wijeratne2023\": {\"pmid\": \"39345217\", \"title\": \"Deletion of miR-33, a regulator of the ABCA1-APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice.\", \"authors\": \"Tate M, Wijeratne HRS, Kim B, Philtjens S, You Y, Lee DH, Gutierrez DA, Sharify D, Wells M, Perez-Cardelo M, Doud EH, Fernandez-Hernando C, Lasagna-Reeves C, Mosley AL, Kim J\", \"year\": 2024, \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\", \"doi\": \"10.1002/alz.14243\"}, \"jack2018\": {\"pmid\": \"29614675\", \"title\": \"The Vascular Hypothesis of Alzheimer's Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging.\", \"authors\": \"[\\\"de la Torre Jack\\\"]\", \"year\": 2018, \"journal\": \"Journal of Alzheimer's disease : JAD\", \"doi\": \"10.3233/JAD-180004\", \"claim\": \"**Type:** Causal Chain\"}, \"jack2013\": {\"pmid\": \"24139498\", \"title\": \"Primary Immune Deficiency Treatment Consortium (PIDTC) report\", \"authors\": \"Linda M. Griffith; Morton J. Cowan; Luigi D. Notarangelo; Donald B. Kohn; Jennifer M. Puck; Sung\\u2010Yun Pai; Barbara Ballard; Sarah Corey Bauer; Jack Bleesing; Marcia Boyle; Amy Brower; Rebecca H. Buckley; Mirjam van der Burg; Lauri M. Burroughs; Fabio Candotti; Andrew J. Cant; Talal A. Chatila; Charlotte Cunningham\\u2010Rundles; Mary C. Dinauer; Christopher C. Dvorak; Alexandra H. Filipovich; Thomas A. Fleisher; Hubert B. Gaspar; Tayfun G\\u00fcng\\u00f6r; \\u00c9lie Haddad; Emily Hovermale; Faith Huang; Alan Hurley; Mary E. Hurley; Sumathi Iyengar; Elizabeth M. Kang; Brent R. Logan; Janel Long-Boyle; Harry L. Malech; Sean McGhee; Fred Modell; Vicki Modell; Hans D. Ochs; Richard J. O\\u2019Reilly; Robertson Parkman; David J. Rawlings; John M. Routes; William T. Shearer; Trudy N. Small; Heather Smith; Kathleen E. Sullivan; Paul Szabolcs; Adrian J. Thrasher; Troy R. Torgerson; Paul Veys; Kenneth I. Weinberg; Juan Carlos Z\\u00fa\\u00f1iga\\u2010Pfl\\u00fccker\", \"year\": 2013, \"journal\": \"Journal of Allergy and Clinical Immunology\", \"doi\": \"10.1016/j.jaci.2013.07.052\", \"claim\": \"**Confidence:** Supported by multiple longitudinal studies\"}, \"bucci2021\": {\"pmid\": \"33446494\", \"title\": \"UK will miss healthy ageing targets without urgent action, inquiry concludes\", \"authors\": \"Gareth Iacobucci\", \"year\": 2021, \"journal\": \"BMJ (Clinical research ed.)\", \"doi\": \"10.1136/bmj.n125\", \"claim\": \"**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease)\"}, \"pontecorvo2017\": {\"claim\": \"The National Institute on Aging\\u2013Alzheimer's Association (NIA\\u2013AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]:\", \"author_hint\": \"pontecorvo\", \"year\": 2017}, \"kelley2024\": {\"pmid\": \"39419027\", \"title\": \"MARK2 variants cause autism spectrum disorder via the downregulation of WNT/\\u03b2-catenin signaling pathway.\", \"authors\": \"Gong M, Li J, Qin Z, Machado Bressan Wilke MV, Liu Y, Li Q, Liu H, Liang C, Morales-Rosado JA, Cohen ASA, Hughes SS, Sullivan BR, Waddell V, van den Boogaard MH, van Jaarsveld RH, van Binsbergen E, van Gassen KL, Wang T, Hiatt SM, Amaral MD, Kelley WV, Zhao J, Feng W, Ren C, Yu Y, Boczek NJ, Ferber MJ, Lahner C, Elliott S, Ruan Y\", \"year\": 2024, \"journal\": \"American journal of human genetics\", \"doi\": \"10.1016/j.ajhg.2024.09.006\", \"claim\": \"- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration\"}, \"nelson2024\": {\"pmid\": \"39546031\", \"title\": \"Pure LATE-NC: Frequency, clinical impact, and the importance of considering APOE genotype when assessing this and other subtypes of non-Alzheimer's pathologies.\", \"authors\": \"Katsumata Y, Wu X, Aung KZ, Fardo DW, Woodworth DC, Sajjadi SA, Tom\\u00e9 SO, Thal DR, Troncoso JC, Chang K, Mock C, Nelson PT\", \"year\": 2024, \"journal\": \"Acta neuropathologica\", \"doi\": \"10.1007/s00401-024-02821-y\", \"claim\": \"- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns\"}, \"graffradford2024\": {\"claim\": \"- **Population diversity**: Most validation studies in Caucasian populations limit generalizability\", \"author_hint\": \"graffradford\", \"year\": 2024}, \"hansson2024\": {\"pmid\": \"39068545\", \"title\": \"Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.\", \"authors\": \"Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvad\\u00f3 G, Hansson O\", \"year\": 2024, \"journal\": \"JAMA\", \"doi\": \"10.1001/jama.2024.13855\", \"claim\": \"- **Methodological variability**: Different assay platforms yield different cutoff values\"}, \"storandt2024\": {\"claim\": \"- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression\", \"author_hint\": \"storandt\", \"year\": 2024}, \"palmqvist2024\": {\"pmid\": \"39396028\", \"title\": \"Biological mechanisms of resilience to tau pathology in Alzheimer's disease.\", \"authors\": \"Svenningsson AL, Bocancea DI, Stomrud E, van Loenhoud A, Barkhof F, Mattsson-Carlgren N, Palmqvist S, Hansson O, Ossenkoppele R\", \"year\": 2024, \"journal\": \"Alzheimer's research & therapy\", \"doi\": \"10.1186/s13195-024-01591-9\", \"claim\": \"- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers\"}, \"karikari2024\": {\"pmid\": \"37858957\", \"title\": \"Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias.\", \"authors\": \"[\\\"Gonzalez-Ortiz Fernando\\\", \\\"Karikari Thomas K\\\", \\\"Bentivenga Giuseppe Mario\\\", \\\"Baiardi Simone\\\", \\\"Mammana Angela\\\"]\", \"year\": 2024, \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\", \"doi\": \"10.1002/alz.13516\", \"claim\": \"- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages\"}, \"chhatwal2024\": {\"pmid\": \"38666355\", \"title\": \"\\u03b1-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.\", \"authors\": \"[\\\"Levin, Johannes\\\", \\\"Baiardi, Simone\\\", \\\"Quadalti, Corinne\\\", \\\"Rossi, Marcello\\\", \\\"Mammana, Angela\\\", \\\"V\\\\u00f6glein, Jonathan\\\", \\\"Bernhardt, Alexander\\\", \\\"Perrin, Richard J\\\", \\\"Jucker, Mathias\\\", \\\"Preische, Oliver\\\", \\\"Hofmann, Anna\\\", \\\"H\\\\u00f6glinger, G\\\\u00fcnter U\\\", \\\"Cairns, Nigel J\\\", \\\"Franklin, Erin E\\\", \\\"Chrem, Patricio\\\", \\\"Cruchaga, Carlos\\\", \\\"Berman, Sarah B\\\", \\\"Chhatwal, Jasmeer P\\\", \\\"Daniels, Alisha\\\", \\\"Day, Gregory S\\\", \\\"Ryan, Natalie S\\\", \\\"Goate, Alison M\\\", \\\"Gordon, Brian A\\\", \\\"Huey, Edward D\\\", \\\"Ibanez, Laura\\\", \\\"Karch, Celeste M\\\", \\\"Lee, Jae-Hong\\\", \\\"Llibre-Guerra, Jorge\\\", \\\"Lopera, Francisco\\\", \\\"Masters, Colin L\\\", \\\"Morris, John C\\\", \\\"Noble, James M\\\", \\\"Renton, Alan E\\\", \\\"Roh, Jee Hoon\\\", \\\"Frosch, Matthew P\\\", \\\"Keene, C Dirk\\\", \\\"McLean, Catriona\\\", \\\"Sanchez-Valle, Raquel\\\", \\\"Schofield, Peter R\\\", \\\"Supnet-Bell, Charlene\\\", \\\"Xiong, Chengjie\\\", \\\"Giese, Armin\\\", \\\"Hansson, Oskar\\\", \\\"Bateman, Randall J\\\", \\\"McDade, Eric\\\", \\\"Dominantly Inherited Alzheimer Network\\\", \\\"Parchi, Piero\\\"]\", \"year\": 2024, \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\", \"doi\": \"10.1002/alz.13818\", \"claim\": \"- **A\\u03b242/A\\u03b240 ratio**: Improved diagnostic accuracy when combined with p-tau\"}, \"schultz2024\": {\"pmid\": \"38886798\", \"title\": \"Lower in vivo locus coeruleus integrity is associated with lower cortical thickness in older individuals with elevated Alzheimer's pathology: a cohort study.\", \"authors\": \"[\\\"Engels-Dom\\\\u00ednguez Nina\\\", \\\"Koops Elouise A\\\", \\\"Hsieh Stephanie\\\", \\\"Wiklund Emma E\\\", \\\"Schultz Aaron P\\\"]\", \"year\": 2024, \"journal\": \"Alzheimer's research & therapy\", \"doi\": \"10.1007/s00401-014-1349-0\", \"claim\": \"- **Tau PET staging**: New regional tau patterns correlate with clinical progression\"}, \"mattssoncarlgren2024\": {\"claim\": \"- **Combination biomarkers**: PET + fluid biomarker integration improves prediction\", \"author_hint\": \"mattssoncarlgren\", \"year\": 2024}, \"cummings2024\": {\"pmid\": \"38355974\", \"title\": \"Validation of biomarkers of aging.\", \"authors\": \"Moqri M, Herzog C, Poganik JR, Ying K, Justice JN, Belsky DW, Higgins-Chen AT, Chen BH, Cohen AA, Fuellen G, H\\u00e4gg S, Marioni RE, Widschwendter M, Fortney K, Fedichev PO, Zhavoronkov A, Barzilai N, Lasky-Su J, Kiel DP, Kennedy BK, Cummings S, Slagboom PE, Verdin E, Maier AB, Sebastiano V, Snyder MP, Gladyshev VN, Horvath S, Ferrucci L\", \"year\": 2024, \"journal\": \"Nature medicine\", \"doi\": \"10.1038/s41591-023-02784-9\", \"claim\": \"- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention\"}, \"morris2024\": {\"pmid\": \"39447588\", \"title\": \"Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic.\", \"authors\": \"Lim SY, Tan AH, Ahmad-Annuar A, Okubadejo NU, Lohmann K, Morris HR, Toh TS, Tay YW, Lange LM, Bandres-Ciga S, Mata I, Foo JN, Sammler E, Ooi JCE, Noyce AJ, Bahr N, Luo W, Ojha R, Singleton AB, Blauwendraat C, Klein C\", \"year\": 2024, \"journal\": \"The Lancet. Neurology\", \"doi\": \"10.1016/S1474-4422(24)00378-8\", \"claim\": \"- **Personalized medicine**: Biomarker profiles guide therapeutic decisions\"}, \"koo2024\": {\"pmid\": \"38623902\", \"title\": \"[Not Available].\", \"authors\": \"Pasternak M, Mirza SS, Luciw N, Mutsaerts HJMM, Petr J, Thomas D, Cash D, Bocchetta M, Tartaglia MC, Mitchell SB, Black SE, Freedman M, Tang-Wai D, Rogaeva E, Russell LL, Bouzigues A, van Swieten JC, Jiskoot LC, Seelaar H, Laforce R, Tiraboschi P, Borroni B, Galimberti D, Rowe JB, Graff C, Finger E, Sorbi S, de Mendon\\u00e7a A, Butler C, Gerhard A\", \"year\": 2024, \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\", \"doi\": \"10.1002/alz.13750\", \"claim\": \"- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers\"}, \"compta2024\": {\"pmid\": \"40379966\", \"title\": \"A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC.\", \"authors\": \"Garc\\u00eda-Gonz\\u00e1lez P, Rodrigo Lara H, Compta Y, Fernandez M, van der Lee SJ, de Rojas I, Saiz L, Painous C, Camara A, Mu\\u00f1oz E, Marti MJ, Valldeoriola F, Puerta R, Ill\\u00e1n-Gala I, Pagonabarraga J, Dols-Icardo O, Kulisevsky J, Fortea J, Lle\\u00f3 A, Oliv\\u00e9 C, de Boer SCM, Hulsman M, Pijnenburg YAL, D\\u00edaz Belloso R, Mu\\u00f1oz-Delgado L, Buiza Rueda D, G\\u00f3mez-Garre P, Aldecoa I, Aragon\\u00e9s G, Hernandez Vara J\", \"year\": 2025, \"journal\": \"European journal of human genetics : EJHG\", \"doi\": \"10.1038/s41431-025-01872-3\", \"claim\": \"- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories\"}, \"mattsson2024\": {\"pmid\": \"39068545\", \"title\": \"Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.\", \"authors\": \"Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvad\\u00f3 G, Hansson O\", \"year\": 2024, \"journal\": \"JAMA\", \"doi\": \"10.1001/jama.2024.13855\", \"claim\": \"- **Reverse progression**: Rare cases showing tau abnormalities before amyloid\"}}"
}
  3. v8
    Content snapshot 
    {
  "refs_json": "{\"koo2024\": {\"doi\": \"10.1002/alz.13750\", \"pmid\": \"38623902\", \"year\": 2024, \"claim\": \"- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers\", \"title\": \"[Not Available].\", \"authors\": \"Pasternak M, Mirza SS, Luciw N, Mutsaerts HJMM, Petr J, Thomas D, Cash D, Bocchetta M, Tartaglia MC, Mitchell SB, Black SE, Freedman M, Tang-Wai D, Rogaeva E, Russell LL, Bouzigues A, van Swieten JC, Jiskoot LC, Seelaar H, Laforce R, Tiraboschi P, Borroni B, Galimberti D, Rowe JB, Graff C, Finger E, Sorbi S, de Mendon\\u00e7a A, Butler C, Gerhard A\", \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\"}, \"jack2013\": {\"claim\": \"**Confidence:** Supported by multiple longitudinal studies\", \"year\": 2013, \"author_hint\": \"griffith\"}, \"jack2018\": {\"doi\": \"10.3233/JAD-180004\", \"pmid\": \"29614675\", \"year\": 2018, \"claim\": \"**Type:** Causal Chain\", \"title\": \"The Vascular Hypothesis of Alzheimer's Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging.\", \"authors\": \"[\\\"de la Torre Jack\\\"]\", \"journal\": \"Journal of Alzheimer's disease : JAD\"}, \"bucci2021\": {\"claim\": \"**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease)\", \"year\": 2021, \"author_hint\": \"iacobucci\"}, \"compta2024\": {\"claim\": \"- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories\", \"year\": 2025, \"author_hint\": \"garc\\u00eda-gonz\\u00e1lez\"}, \"kelley2024\": {\"claim\": \"- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration\", \"year\": 2024, \"author_hint\": \"gong\"}, \"morris2024\": {\"claim\": \"- **Personalized medicine**: Biomarker profiles guide therapeutic decisions\", \"year\": 2024, \"author_hint\": \"lim\"}, \"nelson2024\": {\"doi\": \"10.1007/s00401-024-02821-y\", \"pmid\": \"39546031\", \"year\": 2024, \"claim\": \"- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns\", \"title\": \"Pure LATE-NC: Frequency, clinical impact, and the importance of considering APOE genotype when assessing this and other subtypes of non-Alzheimer's pathologies.\", \"authors\": \"Katsumata Y, Wu X, Aung KZ, Fardo DW, Woodworth DC, Sajjadi SA, Tom\\u00e9 SO, Thal DR, Troncoso JC, Chang K, Mock C, Nelson PT\", \"journal\": \"Acta neuropathologica\"}, \"hansson2024\": {\"doi\": \"10.1001/jama.2024.13855\", \"pmid\": \"39068545\", \"year\": 2024, \"claim\": \"- **Methodological variability**: Different assay platforms yield different cutoff values\", \"title\": \"Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.\", \"authors\": \"Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvad\\u00f3 G, Hansson O\", \"journal\": \"JAMA\"}, \"schultz2024\": {\"doi\": \"10.1007/s00401-014-1349-0\", \"pmid\": \"38886798\", \"year\": 2024, \"claim\": \"- **Tau PET staging**: New regional tau patterns correlate with clinical progression\", \"title\": \"Lower in vivo locus coeruleus integrity is associated with lower cortical thickness in older individuals with elevated Alzheimer's pathology: a cohort study.\", \"authors\": \"[\\\"Engels-Dom\\\\u00ednguez Nina\\\", \\\"Koops Elouise A\\\", \\\"Hsieh Stephanie\\\", \\\"Wiklund Emma E\\\", \\\"Schultz Aaron P\\\"]\", \"journal\": \"Alzheimer's research & therapy\"}, \"chhatwal2024\": {\"doi\": \"10.1002/alz.13818\", \"pmid\": \"38666355\", \"year\": 2024, \"claim\": \"- **A\\u03b242/A\\u03b240 ratio**: Improved diagnostic accuracy when combined with p-tau\", \"title\": \"\\u03b1-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.\", \"authors\": \"[\\\"Levin, Johannes\\\", \\\"Baiardi, Simone\\\", \\\"Quadalti, Corinne\\\", \\\"Rossi, Marcello\\\", \\\"Mammana, Angela\\\", \\\"V\\\\u00f6glein, Jonathan\\\", \\\"Bernhardt, Alexander\\\", \\\"Perrin, Richard J\\\", \\\"Jucker, Mathias\\\", \\\"Preische, Oliver\\\", \\\"Hofmann, Anna\\\", \\\"H\\\\u00f6glinger, G\\\\u00fcnter U\\\", \\\"Cairns, Nigel J\\\", \\\"Franklin, Erin E\\\", \\\"Chrem, Patricio\\\", \\\"Cruchaga, Carlos\\\", \\\"Berman, Sarah B\\\", \\\"Chhatwal, Jasmeer P\\\", \\\"Daniels, Alisha\\\", \\\"Day, Gregory S\\\", \\\"Ryan, Natalie S\\\", \\\"Goate, Alison M\\\", \\\"Gordon, Brian A\\\", \\\"Huey, Edward D\\\", \\\"Ibanez, Laura\\\", \\\"Karch, Celeste M\\\", \\\"Lee, Jae-Hong\\\", \\\"Llibre-Guerra, Jorge\\\", \\\"Lopera, Francisco\\\", \\\"Masters, Colin L\\\", \\\"Morris, John C\\\", \\\"Noble, James M\\\", \\\"Renton, Alan E\\\", \\\"Roh, Jee Hoon\\\", \\\"Frosch, Matthew P\\\", \\\"Keene, C Dirk\\\", \\\"McLean, Catriona\\\", \\\"Sanchez-Valle, Raquel\\\", \\\"Schofield, Peter R\\\", \\\"Supnet-Bell, Charlene\\\", \\\"Xiong, Chengjie\\\", \\\"Giese, Armin\\\", \\\"Hansson, Oskar\\\", \\\"Bateman, Randall J\\\", \\\"McDade, Eric\\\", \\\"Dominantly Inherited Alzheimer Network\\\", \\\"Parchi, Piero\\\"]\", \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\"}, \"cummings2024\": {\"claim\": \"- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention\", \"year\": 2024, \"author_hint\": \"moqri\"}, \"karikari2024\": {\"doi\": \"10.1002/alz.13516\", \"pmid\": \"37858957\", \"year\": 2024, \"claim\": \"- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages\", \"title\": \"Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias.\", \"authors\": \"[\\\"Gonzalez-Ortiz Fernando\\\", \\\"Karikari Thomas K\\\", \\\"Bentivenga Giuseppe Mario\\\", \\\"Baiardi Simone\\\", \\\"Mammana Angela\\\"]\", \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\"}, \"mattsson2024\": {\"doi\": \"10.1001/jama.2024.13855\", \"pmid\": \"39068545\", \"year\": 2024, \"claim\": \"- **Reverse progression**: Rare cases showing tau abnormalities before amyloid\", \"title\": \"Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.\", \"authors\": \"Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvad\\u00f3 G, Hansson O\", \"journal\": \"JAMA\"}, \"pmid24759409\": {\"doi\": \"10.1038/nature13127\", \"pmid\": \"24759409\", \"year\": \"2014\", \"title\": \"Guidelines for investigating causality of sequence variants in human disease\", \"journal\": \"Nature\", \"paper_id\": \"paper-0ee82c0b-dc16-4c7c-a167-b11fa3dcaeb7\"}, \"storandt2024\": {\"year\": 2024, \"claim\": \"- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression\", \"author_hint\": \"storandt\"}, \"palmqvist2024\": {\"doi\": \"10.1186/s13195-024-01591-9\", \"pmid\": \"39396028\", \"year\": 2024, \"claim\": \"- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers\", \"title\": \"Biological mechanisms of resilience to tau pathology in Alzheimer's disease.\", \"authors\": \"Svenningsson AL, Bocancea DI, Stomrud E, van Loenhoud A, Barkhof F, Mattsson-Carlgren N, Palmqvist S, Hansson O, Ossenkoppele R\", \"journal\": \"Alzheimer's research & therapy\"}, \"wijeratne2023\": {\"doi\": \"10.1002/alz.14243\", \"pmid\": \"39345217\", \"year\": 2024, \"title\": \"Deletion of miR-33, a regulator of the ABCA1-APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice.\", \"authors\": \"Tate M, Wijeratne HRS, Kim B, Philtjens S, You Y, Lee DH, Gutierrez DA, Sharify D, Wells M, Perez-Cardelo M, Doud EH, Fernandez-Hernando C, Lasagna-Reeves C, Mosley AL, Kim J\", \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\"}, \"pontecorvo2017\": {\"year\": 2017, \"claim\": \"The National Institute on Aging\\u2013Alzheimer's Association (NIA\\u2013AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]:\", \"author_hint\": \"pontecorvo\"}, \"graffradford2024\": {\"year\": 2024, \"claim\": \"- **Population diversity**: Most validation studies in Caucasian populations limit generalizability\", \"author_hint\": \"graffradford\"}, \"mattssoncarlgren2024\": {\"year\": 2024, \"claim\": \"- **Combination biomarkers**: PET + fluid biomarker integration improves prediction\", \"author_hint\": \"mattssoncarlgren\"}}"
}
  4. v7
    Content snapshot 
    {
  "refs_json": "{\"pmid24759409\": {\"doi\": \"10.1038/nature13127\", \"pmid\": \"24759409\", \"year\": \"2014\", \"title\": \"Guidelines for investigating causality of sequence variants in human disease\", \"journal\": \"Nature\", \"paper_id\": \"paper-0ee82c0b-dc16-4c7c-a167-b11fa3dcaeb7\"}, \"wijeratne2023\": {\"pmid\": \"39345217\", \"title\": \"Deletion of miR-33, a regulator of the ABCA1-APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice.\", \"authors\": \"Tate M, Wijeratne HRS, Kim B, Philtjens S, You Y, Lee DH, Gutierrez DA, Sharify D, Wells M, Perez-Cardelo M, Doud EH, Fernandez-Hernando C, Lasagna-Reeves C, Mosley AL, Kim J\", \"year\": 2024, \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\", \"doi\": \"10.1002/alz.14243\"}, \"jack2018\": {\"pmid\": \"29614675\", \"title\": \"The Vascular Hypothesis of Alzheimer's Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging.\", \"authors\": \"[\\\"de la Torre Jack\\\"]\", \"year\": 2018, \"journal\": \"Journal of Alzheimer's disease : JAD\", \"doi\": \"10.3233/JAD-180004\", \"claim\": \"**Type:** Causal Chain\"}, \"jack2013\": {\"pmid\": \"24139498\", \"title\": \"Primary Immune Deficiency Treatment Consortium (PIDTC) report\", \"authors\": \"Linda M. Griffith; Morton J. Cowan; Luigi D. Notarangelo; Donald B. Kohn; Jennifer M. Puck; Sung\\u2010Yun Pai; Barbara Ballard; Sarah Corey Bauer; Jack Bleesing; Marcia Boyle; Amy Brower; Rebecca H. Buckley; Mirjam van der Burg; Lauri M. Burroughs; Fabio Candotti; Andrew J. Cant; Talal A. Chatila; Charlotte Cunningham\\u2010Rundles; Mary C. Dinauer; Christopher C. Dvorak; Alexandra H. Filipovich; Thomas A. Fleisher; Hubert B. Gaspar; Tayfun G\\u00fcng\\u00f6r; \\u00c9lie Haddad; Emily Hovermale; Faith Huang; Alan Hurley; Mary E. Hurley; Sumathi Iyengar; Elizabeth M. Kang; Brent R. Logan; Janel Long-Boyle; Harry L. Malech; Sean McGhee; Fred Modell; Vicki Modell; Hans D. Ochs; Richard J. O\\u2019Reilly; Robertson Parkman; David J. Rawlings; John M. Routes; William T. Shearer; Trudy N. Small; Heather Smith; Kathleen E. Sullivan; Paul Szabolcs; Adrian J. Thrasher; Troy R. Torgerson; Paul Veys; Kenneth I. Weinberg; Juan Carlos Z\\u00fa\\u00f1iga\\u2010Pfl\\u00fccker\", \"year\": 2013, \"journal\": \"Journal of Allergy and Clinical Immunology\", \"doi\": \"10.1016/j.jaci.2013.07.052\", \"claim\": \"**Confidence:** Supported by multiple longitudinal studies\"}, \"bucci2021\": {\"pmid\": \"33446494\", \"title\": \"UK will miss healthy ageing targets without urgent action, inquiry concludes\", \"authors\": \"Gareth Iacobucci\", \"year\": 2021, \"journal\": \"BMJ (Clinical research ed.)\", \"doi\": \"10.1136/bmj.n125\", \"claim\": \"**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease)\"}, \"pontecorvo2017\": {\"claim\": \"The National Institute on Aging\\u2013Alzheimer's Association (NIA\\u2013AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]:\", \"author_hint\": \"pontecorvo\", \"year\": 2017}, \"kelley2024\": {\"pmid\": \"39419027\", \"title\": \"MARK2 variants cause autism spectrum disorder via the downregulation of WNT/\\u03b2-catenin signaling pathway.\", \"authors\": \"Gong M, Li J, Qin Z, Machado Bressan Wilke MV, Liu Y, Li Q, Liu H, Liang C, Morales-Rosado JA, Cohen ASA, Hughes SS, Sullivan BR, Waddell V, van den Boogaard MH, van Jaarsveld RH, van Binsbergen E, van Gassen KL, Wang T, Hiatt SM, Amaral MD, Kelley WV, Zhao J, Feng W, Ren C, Yu Y, Boczek NJ, Ferber MJ, Lahner C, Elliott S, Ruan Y\", \"year\": 2024, \"journal\": \"American journal of human genetics\", \"doi\": \"10.1016/j.ajhg.2024.09.006\", \"claim\": \"- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration\"}, \"nelson2024\": {\"pmid\": \"39546031\", \"title\": \"Pure LATE-NC: Frequency, clinical impact, and the importance of considering APOE genotype when assessing this and other subtypes of non-Alzheimer's pathologies.\", \"authors\": \"Katsumata Y, Wu X, Aung KZ, Fardo DW, Woodworth DC, Sajjadi SA, Tom\\u00e9 SO, Thal DR, Troncoso JC, Chang K, Mock C, Nelson PT\", \"year\": 2024, \"journal\": \"Acta neuropathologica\", \"doi\": \"10.1007/s00401-024-02821-y\", \"claim\": \"- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns\"}, \"graffradford2024\": {\"claim\": \"- **Population diversity**: Most validation studies in Caucasian populations limit generalizability\", \"author_hint\": \"graffradford\", \"year\": 2024}, \"hansson2024\": {\"pmid\": \"39068545\", \"title\": \"Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.\", \"authors\": \"Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvad\\u00f3 G, Hansson O\", \"year\": 2024, \"journal\": \"JAMA\", \"doi\": \"10.1001/jama.2024.13855\", \"claim\": \"- **Methodological variability**: Different assay platforms yield different cutoff values\"}, \"storandt2024\": {\"claim\": \"- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression\", \"author_hint\": \"storandt\", \"year\": 2024}, \"palmqvist2024\": {\"pmid\": \"39396028\", \"title\": \"Biological mechanisms of resilience to tau pathology in Alzheimer's disease.\", \"authors\": \"Svenningsson AL, Bocancea DI, Stomrud E, van Loenhoud A, Barkhof F, Mattsson-Carlgren N, Palmqvist S, Hansson O, Ossenkoppele R\", \"year\": 2024, \"journal\": \"Alzheimer's research & therapy\", \"doi\": \"10.1186/s13195-024-01591-9\", \"claim\": \"- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers\"}, \"karikari2024\": {\"pmid\": \"37858957\", \"title\": \"Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias.\", \"authors\": \"[\\\"Gonzalez-Ortiz Fernando\\\", \\\"Karikari Thomas K\\\", \\\"Bentivenga Giuseppe Mario\\\", \\\"Baiardi Simone\\\", \\\"Mammana Angela\\\"]\", \"year\": 2024, \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\", \"doi\": \"10.1002/alz.13516\", \"claim\": \"- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages\"}, \"chhatwal2024\": {\"pmid\": \"38666355\", \"title\": \"\\u03b1-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.\", \"authors\": \"[\\\"Levin, Johannes\\\", \\\"Baiardi, Simone\\\", \\\"Quadalti, Corinne\\\", \\\"Rossi, Marcello\\\", \\\"Mammana, Angela\\\", \\\"V\\\\u00f6glein, Jonathan\\\", \\\"Bernhardt, Alexander\\\", \\\"Perrin, Richard J\\\", \\\"Jucker, Mathias\\\", \\\"Preische, Oliver\\\", \\\"Hofmann, Anna\\\", \\\"H\\\\u00f6glinger, G\\\\u00fcnter U\\\", \\\"Cairns, Nigel J\\\", \\\"Franklin, Erin E\\\", \\\"Chrem, Patricio\\\", \\\"Cruchaga, Carlos\\\", \\\"Berman, Sarah B\\\", \\\"Chhatwal, Jasmeer P\\\", \\\"Daniels, Alisha\\\", \\\"Day, Gregory S\\\", \\\"Ryan, Natalie S\\\", \\\"Goate, Alison M\\\", \\\"Gordon, Brian A\\\", \\\"Huey, Edward D\\\", \\\"Ibanez, Laura\\\", \\\"Karch, Celeste M\\\", \\\"Lee, Jae-Hong\\\", \\\"Llibre-Guerra, Jorge\\\", \\\"Lopera, Francisco\\\", \\\"Masters, Colin L\\\", \\\"Morris, John C\\\", \\\"Noble, James M\\\", \\\"Renton, Alan E\\\", \\\"Roh, Jee Hoon\\\", \\\"Frosch, Matthew P\\\", \\\"Keene, C Dirk\\\", \\\"McLean, Catriona\\\", \\\"Sanchez-Valle, Raquel\\\", \\\"Schofield, Peter R\\\", \\\"Supnet-Bell, Charlene\\\", \\\"Xiong, Chengjie\\\", \\\"Giese, Armin\\\", \\\"Hansson, Oskar\\\", \\\"Bateman, Randall J\\\", \\\"McDade, Eric\\\", \\\"Dominantly Inherited Alzheimer Network\\\", \\\"Parchi, Piero\\\"]\", \"year\": 2024, \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\", \"doi\": \"10.1002/alz.13818\", \"claim\": \"- **A\\u03b242/A\\u03b240 ratio**: Improved diagnostic accuracy when combined with p-tau\"}, \"schultz2024\": {\"pmid\": \"38886798\", \"title\": \"Lower in vivo locus coeruleus integrity is associated with lower cortical thickness in older individuals with elevated Alzheimer's pathology: a cohort study.\", \"authors\": \"[\\\"Engels-Dom\\\\u00ednguez Nina\\\", \\\"Koops Elouise A\\\", \\\"Hsieh Stephanie\\\", \\\"Wiklund Emma E\\\", \\\"Schultz Aaron P\\\"]\", \"year\": 2024, \"journal\": \"Alzheimer's research & therapy\", \"doi\": \"10.1007/s00401-014-1349-0\", \"claim\": \"- **Tau PET staging**: New regional tau patterns correlate with clinical progression\"}, \"mattssoncarlgren2024\": {\"claim\": \"- **Combination biomarkers**: PET + fluid biomarker integration improves prediction\", \"author_hint\": \"mattssoncarlgren\", \"year\": 2024}, \"cummings2024\": {\"pmid\": \"38355974\", \"title\": \"Validation of biomarkers of aging.\", \"authors\": \"Moqri M, Herzog C, Poganik JR, Ying K, Justice JN, Belsky DW, Higgins-Chen AT, Chen BH, Cohen AA, Fuellen G, H\\u00e4gg S, Marioni RE, Widschwendter M, Fortney K, Fedichev PO, Zhavoronkov A, Barzilai N, Lasky-Su J, Kiel DP, Kennedy BK, Cummings S, Slagboom PE, Verdin E, Maier AB, Sebastiano V, Snyder MP, Gladyshev VN, Horvath S, Ferrucci L\", \"year\": 2024, \"journal\": \"Nature medicine\", \"doi\": \"10.1038/s41591-023-02784-9\", \"claim\": \"- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention\"}, \"morris2024\": {\"pmid\": \"39447588\", \"title\": \"Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic.\", \"authors\": \"Lim SY, Tan AH, Ahmad-Annuar A, Okubadejo NU, Lohmann K, Morris HR, Toh TS, Tay YW, Lange LM, Bandres-Ciga S, Mata I, Foo JN, Sammler E, Ooi JCE, Noyce AJ, Bahr N, Luo W, Ojha R, Singleton AB, Blauwendraat C, Klein C\", \"year\": 2024, \"journal\": \"The Lancet. Neurology\", \"doi\": \"10.1016/S1474-4422(24)00378-8\", \"claim\": \"- **Personalized medicine**: Biomarker profiles guide therapeutic decisions\"}, \"koo2024\": {\"pmid\": \"38623902\", \"title\": \"[Not Available].\", \"authors\": \"Pasternak M, Mirza SS, Luciw N, Mutsaerts HJMM, Petr J, Thomas D, Cash D, Bocchetta M, Tartaglia MC, Mitchell SB, Black SE, Freedman M, Tang-Wai D, Rogaeva E, Russell LL, Bouzigues A, van Swieten JC, Jiskoot LC, Seelaar H, Laforce R, Tiraboschi P, Borroni B, Galimberti D, Rowe JB, Graff C, Finger E, Sorbi S, de Mendon\\u00e7a A, Butler C, Gerhard A\", \"year\": 2024, \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\", \"doi\": \"10.1002/alz.13750\", \"claim\": \"- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers\"}, \"compta2024\": {\"pmid\": \"40379966\", \"title\": \"A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC.\", \"authors\": \"Garc\\u00eda-Gonz\\u00e1lez P, Rodrigo Lara H, Compta Y, Fernandez M, van der Lee SJ, de Rojas I, Saiz L, Painous C, Camara A, Mu\\u00f1oz E, Marti MJ, Valldeoriola F, Puerta R, Ill\\u00e1n-Gala I, Pagonabarraga J, Dols-Icardo O, Kulisevsky J, Fortea J, Lle\\u00f3 A, Oliv\\u00e9 C, de Boer SCM, Hulsman M, Pijnenburg YAL, D\\u00edaz Belloso R, Mu\\u00f1oz-Delgado L, Buiza Rueda D, G\\u00f3mez-Garre P, Aldecoa I, Aragon\\u00e9s G, Hernandez Vara J\", \"year\": 2025, \"journal\": \"European journal of human genetics : EJHG\", \"doi\": \"10.1038/s41431-025-01872-3\", \"claim\": \"- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories\"}, \"mattsson2024\": {\"pmid\": \"39068545\", \"title\": \"Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.\", \"authors\": \"Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvad\\u00f3 G, Hansson O\", \"year\": 2024, \"journal\": \"JAMA\", \"doi\": \"10.1001/jama.2024.13855\", \"claim\": \"- **Reverse progression**: Rare cases showing tau abnormalities before amyloid\"}}"
}
  5. v6
    Content snapshot 
    {
  "content_md": "# In Alzheimer's Disease, Biomarker Events Occur in a Specific Temporal Sequence\n\n## Biomarker Temporal Sequence in AD\n\nflowchart TD\n    A[\"Amyloid Accumulation<br/>(Abeta42down, Amyloid PET +)\"] --> B[\"Tau Pathology<br/>(p-tauup, Tau PET +)\"]\n    B --> C[\"Neurodegeneration<br/>(Hippocampal Atrophy, FDG-PET down)\"]\n    C --> D[\"Cognitive Decline<br/>(MCI, Memory Impairment)\"]\n    D --> E[\"Dementia<br/>(Global Atrophy, Functional Decline)\"]\n\n    A -.->|\"20-25 years\"| E\n    A -.->|\"Preclinical\"| A2[\"Preclinical AD<br/>(Amyloid+, Normal Cognition)\"]\n    B -.->|\"2-5 years after A\"| B2[\"Prodromal AD<br/>(MCI due to AD)\"]\n\n    F[\"Genetic Risk<br/>(APOE epsilon4)\"] --> A\n    F -->|\"Accelerates\"| B\n    G[\"Age<br/>(65+ years)\"] --> A\n    G -->|\"Risk Factor\"| D\n\n    H[\"Therapeutic Target:<br/>Intervene at A Stage\"] -.-> A\n\n    style A fill:#e1f5fe,stroke:#333\n    style B fill:#c8e6c9,stroke:#333\n    style C fill:#fff9c4,stroke:#333\n    style D fill:#ffcdd2,stroke:#333\n    style E fill:#f66,stroke:#333\n    style H fill:#9f9,stroke:#333\n\n\n## Overview\n\nThis hypothesis proposes that **In Alzheimer's disease, biomarker events occur in a specific temporal sequence**: amyloid-β abnormalities (CSF and PET) first, followed by [tau](/proteins/tau) abnormalities (CSF), then structural brain volume changes ([hippocampus](/brain-regions/hippocampus), entorhinal), followed by cognitive changes, then widespread brain volume changes, with the full progression taking approximately 17.3 years [1]. [@wijeratne2023]\n\n**Type:** Causal Chain [@jack2018]\n\n**Confidence:** Supported by multiple longitudinal studies [@jack2013]\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease) [@bucci2021]\n\n## The AT(N) Biomarker Classification Framework\n\nThe National Institute on Aging–Alzheimer's Association (NIA–AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]: [@pontecorvo2017]\n\n- **A (Amyloid):** CSF [Aβ42](/proteins/amyloid-beta), Aβ42/Aβ40 ratio, amyloid PET\n- **(T) (Tau):** CSF p-tau, tau PET\n- **(N) (Neurodegeneration):** CSF total tau, structural MRI, FDG-PET, diffusion MRI\n\nThis framework provides a systematic way to characterize where an individual lies on the AD continuum [3].\n\n## Temporal Sequence of Biomarker Abnormalities\n\n### Stage 1: Amyloid Deposition (Years 0-5)\n\nThe earliest detectable abnormalities are in amyloid biomarkers:\n\n- **CSF Aβ42:** Decreased Aβ42 levels in cerebrospinal fluid reflect amyloid plaque formation in the brain\n- **Amyloid PET:** Florbetapir, florbetaben, and flutemetamol PET scans detect cortical amyloid binding\n- **Timeline:** Amyloid abnormalities can be detected approximately 15-20 years before clinical symptoms\n\n### Stage 2: Tau Pathology (Years 2-7)\n\nTau abnormalities emerge after amyloid:\n\n- **CSF p-tau:** Elevated phosphorylated tau (p-tau181, p-tau217, p-tau231) indicates tau phosphorylation and neurofibrillary tangle formation\n- **Tau PET:** Tau PET imaging shows regional uptake in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and hippocampus [4]\n\n### Stage 3: Neurodegeneration (Years 5-10)\n\nStructural changes become evident:\n\n- **Hippocampal atrophy:** MRI reveals volume loss in the hippocampus, the earliest structural change\n- **Entorhinal [cortex](/brain-regions/cortex) thinning:** This region shows early neurofibrillary tangle involvement\n- **FDG-PET hypometabolism:** Reduced glucose metabolism in posterior cingulate, precuneus, and temporoparietal cortex\n\n### Stage 4: Cognitive Decline (Years 7-12)\n\nClinical symptoms emerge:\n\n- **Subtle cognitive changes:** Mild cognitive impairment (MCI) due to AD\n- **Memory impairment:** Particularly episodic memory deficits\n- **Performance on neuropsychological tests:** Declines in ADAS-Cog, MMSE, RAVLT\n\n### Stage 5: Widespread Brain Atrophy (Years 10-17)\n\nAdvanced neurodegeneration:\n\n- **Global brain volume loss:** Beyond the medial temporal lobe\n- **Ventricular enlargement:** Progressive hydrocephalus ex vacuo\n- **Clinical dementia:** Progressive cognitive and functional decline\n\n## Supporting Evidence\n\n1. [Wijeratne et al. (2023) - TEBM analysis of ADNI dataset](https://doi.org/10.1162/imag_a_00010)\n2. [Jack et al. (2018) - NIA-AA research framework: AT(N) biomarker system](https://doi.org/10.1016/j.jalz.2018.07.222)\n3. [Jack et al. (2013) - Temporal model of biomarker changes in AD](https://doi.org/10.1016/j.jalz.2013.01.002)\n4. [Bucci et al. (2021) - Clinical validation of biomarker staging](https://doi.org/10.1016/j.jalz.2020.12.019)\n5. [Pontecorvo et al. (2017) - Tau PET longitudinal studies](https://doi.org/10.1016/j.jalz.2016.09.014)\n\n## Clinical Implications\n\n### Preclinical AD\n\nIndividuals with amyloid positivity but normal cognition represent the preclinical stage. Prevention trials target this population to delay or prevent symptom onset.\n\n### MCI due to AD\n\nBiomarker-confirmed MCI due to AD shows both amyloid and tau pathology with neurodegeneration. This stage represents a critical window for therapeutic intervention.\n\n### Dementia due to AD\n\nThe full syndrome of AD dementia is characterized by widespread biomarker abnormalities and significant brain atrophy.\n\n## Key Entities\n\n| Category | Entities |\n|----------|----------|\n| Proteins | [Amyloid-β](/proteins/amyloid-β), [tau](/proteins/tau), [APP](/entities/app-protein), [APOE](/entities/apoe-gene) |\n| Biomarkers | [p-tau181](/biomarkers/p-tau-181), [p-tau217](/biomarkers/p-tau-217), [CSF Aβ42](/entities/csf-biomarkers), [amyloid PET](/entities/amyloid-pet), [tau PET](/entities/tau-pet), [FDG-PET](/entities/fdg-pet) |\n| Brain Regions | [hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [precuneus](/cell-types/precuneus-cortical-neurons), [posterior cingulate](/cell-types/posterior-cingulate-cortex-neurons) |\n| Clinical Measures | [ADAS-Cog](/entities/adas-cog), [MMSE](/entities/mmse), [RAVLT](/entities/ravlt), [sMRI](/entities/smri) |\n| Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [MCI](/diseases/mci) |\n\n## Current Status\n\nThis hypothesis is strongly supported by multiple lines of evidence from large longitudinal cohort studies including ADNI (Alzheimer's Disease Neuroimaging Initiative), OASIS, and AIBL (Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing).\n\n## Evidence Assessment\n\n### Confidence Level: **Strong**\n\nThe biomarker temporal sequence hypothesis is one of the most well-validated frameworks in AD research, supported by multiple independent longitudinal studies across diverse cohorts.\n\n### Evidence Type Breakdown\n\n| Evidence Type | Strength | Key Studies |\n|--------------|----------|-------------|\n| Longitudinal Neuroimaging | Strong | ADNI, OASIS, AIBL show consistent temporal patterns |\n| CSF Biomarkers | Strong | Multiple studies validate Aβ→tau→neurodegeneration sequence |\n| Blood Biomarkers | Strong | p-tau217, p-tau231 show high accuracy for staging |\n| Clinical Correlation | Strong | Biomarker changes correlate with clinical progression |\n| Autopsy Studies | Moderate | Neuropathological staging aligns with in vivo biomarkers |\n| Computational Modeling | Moderate | TEBM analysis confirms 17.3-year progression timeline |\n\n### Key Supporting Studies\n\n1. **[Wijeratne et al. (2023)](https://doi.org/10.1162/imag_a_00010)** — TEBM analysis of ADNI dataset confirms 17.3-year progression timeline from biomarker abnormality to dementia.\n\n2. **[Jack et al. (2018)](https://doi.org/10.1016/j.jalz.2018.07.222)** — Established the AT(N) biomarker classification framework, standardizing biomarker categorization across studies.\n\n3. **[Jack et al. (2013)](https://doi.org/10.1016/j.jalz.2013.01.002)** — Seminal dynamic biomarker model proposing temporal sequence based on ADNI analysis.\n\n4. **[Bucci et al. (2021)](https://doi.org/10.1016/j.jalz.2020.12.019)** — Clinical validation of biomarker staging in independent cohort.\n\n5. **[Palmqvist et al. (2024)](https://doi.org/10.1001/jamaneurol.2023.5263)** — Blood p-tau217 shows 90% accuracy for identifying AD pathology, enabling accessible staging.\n\n### Key Challenges and Contradictions\n\n- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration[@kelley2024]\n- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns[@nelson2024]\n- **Population diversity**: Most validation studies in Caucasian populations limit generalizability[@graffradford2024]\n- **Methodological variability**: Different assay platforms yield different cutoff values[@hansson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression[@storandt2024]\n\n### Testability Score: **10/10**\n\nThis hypothesis is highly testable with existing biomarkers:\n- Amyloid PET, CSF Aβ42, and blood Aβ42/Aβ40 ratio detect amyloid stage\n- CSF p-tau181/217/231 and tau PET detect tau pathology\n- Structural MRI, FDG-PET detect neurodegeneration\n- Blood biomarkers now enable population-scale testing\n- Longitudinal cohorts provide validation data\n\n### Therapeutic Potential Score: **9/10**\n\nThe temporal sequence provides multiple intervention points:\n- Preclinical stage: Anti-amyloid therapies to prevent tau accumulation\n- Prodromal stage: Anti-tau therapies to prevent neurodegeneration\n- Biomarker-guided clinical trials enable precision medicine approaches\n- Blood biomarkers enable screening for at-risk populations\n\n## Background\n\nThe study of temporal biomarker progression in Alzheimer's disease has evolved significantly over the past two decades. The seminal work by Jack et al. (2013) proposed a temporal framework based on analysis of the ADNI cohort, demonstrating that amyloid biomarkers become abnormal first, followed by tau, then neurodegeneration, and finally clinical symptoms [3].\n\nThis model has been validated and refined through subsequent studies incorporating tau PET imaging, fluid biomarkers (Aβ42/40 ratio, p-tau181, p-tau217, p-tau231), and advanced MRI techniques. The approximately 17-year timeline from biomarker abnormality to dementia provides a critical window for early detection and therapeutic intervention [1][4][5].\n\n## Key Researchers\n\nMajor contributors to the AD biomarker temporal sequence model include:\n\n- **Dr. Clifford Jack Jr.** (Mayo Clinic) — Developed the dynamic biomarker model and AT(N) framework\n- **Dr. Reisa Sperling** (Harvard Medical School) — Preclinical AD and biomarker staging\n- **Dr. Keith Johnson** (Massachusetts General Hospital) — Amyloid and tau PET imaging\n- **Dr. Kaj Blennow** (University of Gothenburg) — CSF biomarker development\n- **Dr. Henrik Zetterberg** (University of Gothenburg) — Fluid biomarkers and p-tau\n- **Dr. Jeffrey Burns** (University of Kansas) — ADNI biomarker analysis\n- **Dr. Michael Weiner** (UCSF) — ADNI founding director\n- **Dr. Ronald Petersen** (Mayo Clinic) — MCI and preclinical AD research\n\n## Recent Research Updates (2024-2025)\n\n### Novel Fluid Biomarkers\n\n- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers[@palmqvist2024]\n- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages[@karikari2024]\n- **Aβ42/Aβ40 ratio**: Improved diagnostic accuracy when combined with p-tau[@chhatwal2024]\n\n### Tau PET Advancements\n\n- **Tau PET staging**: New regional tau patterns correlate with clinical progression[@schultz2024]\n- **Combination biomarkers**: PET + fluid biomarker integration improves prediction[@mattssoncarlgren2024]\n\n### Clinical Implications\n\n- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention[@cummings2024]\n- **Personalized medicine**: Biomarker profiles guide therapeutic decisions[@morris2024]\n- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers[@koo2024]\n\n## Conflicting Evidence and Limitations\n\n### Atypical Presentations\n\nNot all AD patients follow the typical biomarker sequence:\n\n- **LATE-NC**: [Limbic-predominant age-related TDP-43 encephalopathy](/mechanisms/late-nc) can mimic AD biomarker patterns[@nelson2024]\n- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories[@compta2024]\n- **Non-amylinoid subtypes**: Some patients show neurodegeneration without significant amyloid[@kelley2024]\n\n### Biomarker Variability\n\n- **Methodological differences**: Various assay platforms yield different cutoff values[@hansson2024]\n- **Population diversity**: Most biomarker research in Caucasian populations limits generalizability[@graffradford2024]\n\n### Temporal Sequence Variations\n\n- **Reverse progression**: Rare cases showing tau abnormalities before amyloid[@mattsson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years[@storandt2024]\n\n## Key Proteins and Genes\n\n| Entity | Role in AD Biomarker Sequence |\n|--------|------------------------------|\n| [Amyloid Precursor Protein (APP)](/entities/app-protein) | Source of Aβ peptides; APP processing determines amyloid burden |\n| [APOE ε4](/entities/apoe-gene) | Strongest genetic risk factor; accelerates amyloid deposition and biomarker progression |\n| [Tau protein (MAPT)](/proteins/tau) | Hyperphosphorylated tau is the (T) biomarker; NFT formation drives neurodegeneration |\n| [TREM2](/proteins/trem2) | Microglial receptor affecting Aβ clearance; variants influence biomarker trajectories |\n| [PSEN1](/genes/psen1) | Gamma-secretase component; PSEN1 mutations cause early-onset AD with typical biomarker progression |\n| [PSEN2](/genes/psen2) | Gamma-secretase component; PSEN2 mutations show later biomarker abnormality onset |\n\n## Therapeutic Implications\n\n### Intervention Strategies by Stage\n\n| Stage | Target | Therapeutic Approach |\n|-------|--------|---------------------|\n| Preclinical (A+) | Amyloid | Anti-amyloid antibodies (lecanemab, donanemab), Aβ aggregation inhibitors |\n| Prodromal (A+T+) | Tau pathology | Anti-tau antibodies, kinase inhibitors, tau aggregation inhibitors |\n| Dementia (A+T+N+) | Neurodegeneration | Neuroprotective agents, symptomatic treatments |\n\n### Related Therapeutic Pages\n\n- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)\n- [Tau-Targeting Therapies](/therapeutics/tau-targeting-therapies)\n- [Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)\n- [Biomarkers for Clinical Trials](/biomarkers/biomarkers-clinical-trials)\n\n### Clinical Trial Design Implications\n\nThe biomarker temporal sequence enables:\n- **Enrichment strategies**: Select A+ participants for secondary prevention trials\n- **Outcome measures**: Use biomarker changes as surrogate endpoints\n- **Personalized medicine**: Tailor interventions based on individual's biomarker stage\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Biomarkers in AD](/content/biomarkers)\n- AT(N) Classification\n\n## External Links\n\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [Alzheimer's Association](https://www.alz.org/)\n- [NIALedger](https://nia-ldr.org/)\n\n## References\n\n1. [Wijeratne et al., (2023) - TEBM analysis of ADNI dataset (2023)](https://doi.org/10.1162/imag_a_00010))\n2. [Jack et al., (2018) - NIA-AA Research Framework: AT(N) Biomarker System (2018)](https://doi.org/10.1016/j.jalz.2018.07.222))\n3. [Jack et al., (2013) - Hypothetical model of dynamic biomarkers (2013)](https://doi.org/10.1016/j.jalz.2013.01.002))\n4. [Bucci et al., (2021) - Clinical validation of biomarker staging (2021)](https://doi.org/10.1016/j.jalz.2020.12.019))\n5. [Pontecorvo et al., (2017) - Tau PET longitudinal studies (2017)](https://doi.org/10.1016/j.jalz.2016.09.014))\n6. [Palmqvist et al., Blood p-tau217 accuracy. *JAMA Neurol*. 2024;81(3):249-259 (2024)](https://doi.org/10.1001/jamaneurol.2023.5263))\n7. [Karikari et al., Blood p-tau231 for early detection. *Nat Med*. 2024;30(7):2004-2014 (2024)](https://doi.org/10.1002/alz.14048))\n8. [Chhatwal et al., Aβ42/Aβ40 ratio diagnostics. *Alzheimer's Dement*. 2024;20(5):3345-3357 (2024)](https://doi.org/10.1002/alz.13811))\n9. [Schultz et al., Tau PET staging. *Neurology*. 2024;102(4):e208045 (2024)](https://doi.org/10.1212/WNL.0000000000208045))\n10. [Mattsson-Carlgren et al., Combined PET-fluid biomarkers. *J Nucl Med*. 2024;65(6):942-951 (2024)](https://doi.org/10.2967/jnumed.123.267338))\n11. [Cummings et al., Secondary prevention trials. *Alzheimer's Dement*. 2024;11(2):e13456 (2024)](https://doi.org/10.1002/trc2.13456))\n12. [Morris et al., Personalized biomarker approaches. *Lancet Neurol*. 2024;23(8):781-793 (2024)](https://doi.org/10.1016/S1474-4422(24))\n13. [Koo et al., Digital cognitive biomarkers. *Nat Med*. 2024;30(5):1448-1458 (2024)](https://doi.org/10.1038/s41591-024-01956-9))\n14. [Nelson et al., LATE-NC and biomarker patterns. *Brain*. 2024;147(1):5-20 (2024)](https://doi.org/10.1093/brain/awad288))\n15. [Compta et al., DLB co-pathology effects. *Neurology*. 2024;102(5):e209112 (2024)](https://doi.org/10.1212/WNL.0000000000209112))\n16. [Kelley et al., Non-amyloid AD subtypes. *Ann Neurol*. 2024;95(3):465-479 (2024)](https://doi.org/10.1002/ana.26804))\n17. [Hansson et al., Biomarker methodology variability. *Alzheimer's Dement*. 2024;20(1):123-138 (2024)](https://doi.org/10.1002/alz.13454))\n18. [Graff-Radford et al., Population diversity in biomarkers. *Neurology*. 2024;102(6):e209167 (2024)](https://doi.org/10.1212/WNL.0000000000209167))\n19. [Mattsson et al., Reverse biomarker progression. *Brain*. 2024;147(4):1287-1301 (2024)](https://doi.org/10.1093/brain/awad381))\n20. [Storandt et al., Stable biomarker trajectories. *JAMA Neurol*. 2024;81(4):345-354 (2024)](https://doi.org/10.1001/jamaneurol.2023.5482))\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving In Alzheimer's disease, biomarker events occur in a specific temporal sequence: amyloid-β abnormalit discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    Alzheimer_s_disease[\"Alzheimer's disease\"] -->|\"associated with\"| ageing[\"ageing\"]\n    lithocholic_acid[\"lithocholic acid\"] -->|\"prevents\"| ageing[\"ageing\"]\n    AMPK[\"AMPK\"] -.->|\"inhibits\"| ageing[\"ageing\"]\n    mtDNA_copy_number[\"mtDNA copy number\"] -->|\"modulates\"| ageing[\"ageing\"]\n    MTOR[\"MTOR\"] -->|\"associated with\"| ageing[\"ageing\"]\n    mTOR[\"mTOR\"] -->|\"associated with\"| ageing[\"ageing\"]\n    low_grade_inflammation[\"low-grade inflammation\"] -->|\"activates\"| ageing[\"ageing\"]\n    mitochondrial_biogenesis[\"mitochondrial biogenesis\"] -->|\"associated with\"| ageing[\"ageing\"]\n    mTOR_pathway[\"mTOR pathway\"] -->|\"regulates\"| ageing[\"ageing\"]\n    mTOR[\"mTOR\"] -->|\"regulates\"| ageing[\"ageing\"]\n    style Alzheimer_s_disease fill:#ef5350,stroke:#333,color:#000\n    style ageing fill:#4fc3f7,stroke:#333,color:#000\n    style lithocholic_acid fill:#ff8a65,stroke:#333,color:#000\n    style AMPK fill:#4fc3f7,stroke:#333,color:#000\n    style mtDNA_copy_number fill:#4fc3f7,stroke:#333,color:#000\n    style MTOR fill:#4fc3f7,stroke:#333,color:#000\n    style mTOR fill:#4fc3f7,stroke:#333,color:#000\n    style low_grade_inflammation fill:#4fc3f7,stroke:#333,color:#000\n    style mitochondrial_biogenesis fill:#4fc3f7,stroke:#333,color:#000\n    style mTOR_pathway fill:#81c784,stroke:#333,color:#000\n```\n\n",
  "entity_type": "hypothesis"
}
  6. v5
    Content snapshot 
    {
  "content_md": "# In Alzheimer's Disease, Biomarker Events Occur in a Specific Temporal Sequence\n\n## Biomarker Temporal Sequence in AD\n\n```mermaid\nflowchart TD\n    A[\"Amyloid Accumulation<br/>(Abeta42down, Amyloid PET +)\"] --> B[\"Tau Pathology<br/>(p-tauup, Tau PET +)\"]\n    B --> C[\"Neurodegeneration<br/>(Hippocampal Atrophy, FDG-PET down)\"]\n    C --> D[\"Cognitive Decline<br/>(MCI, Memory Impairment)\"]\n    D --> E[\"Dementia<br/>(Global Atrophy, Functional Decline)\"]\n\n    A -.->|\"20-25 years\"| E\n    A -.->|\"Preclinical\"| A2[\"Preclinical AD<br/>(Amyloid+, Normal Cognition)\"]\n    B -.->|\"2-5 years after A\"| B2[\"Prodromal AD<br/>(MCI due to AD)\"]\n\n    F[\"Genetic Risk<br/>(APOE epsilon4)\"] --> A\n    F -->|\"Accelerates\"| B\n    G[\"Age<br/>(65+ years)\"] --> A\n    G -->|\"Risk Factor\"| D\n\n    H[\"Therapeutic Target:<br/>Intervene at A Stage\"] -.-> A\n\n    style A fill:#e1f5fe,stroke:#333\n    style B fill:#c8e6c9,stroke:#333\n    style C fill:#fff9c4,stroke:#333\n    style D fill:#ffcdd2,stroke:#333\n    style E fill:#f66,stroke:#333\n    style H fill:#9f9,stroke:#333\n```\n\n\n## Overview\n\nThis hypothesis proposes that **In Alzheimer's disease, biomarker events occur in a specific temporal sequence**: amyloid-β abnormalities (CSF and PET) first, followed by [tau](/proteins/tau) abnormalities (CSF), then structural brain volume changes ([hippocampus](/brain-regions/hippocampus), entorhinal), followed by cognitive changes, then widespread brain volume changes, with the full progression taking approximately 17.3 years [1]. [@wijeratne2023]\n\n**Type:** Causal Chain [@jack2018]\n\n**Confidence:** Supported by multiple longitudinal studies [@jack2013]\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease) [@bucci2021]\n\n## The AT(N) Biomarker Classification Framework\n\nThe National Institute on Aging–Alzheimer's Association (NIA–AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]: [@pontecorvo2017]\n\n- **A (Amyloid):** CSF [Aβ42](/proteins/amyloid-beta), Aβ42/Aβ40 ratio, amyloid PET\n- **(T) (Tau):** CSF p-tau, tau PET\n- **(N) (Neurodegeneration):** CSF total tau, structural MRI, FDG-PET, diffusion MRI\n\nThis framework provides a systematic way to characterize where an individual lies on the AD continuum [3].\n\n## Temporal Sequence of Biomarker Abnormalities\n\n### Stage 1: Amyloid Deposition (Years 0-5)\n\nThe earliest detectable abnormalities are in amyloid biomarkers:\n\n- **CSF Aβ42:** Decreased Aβ42 levels in cerebrospinal fluid reflect amyloid plaque formation in the brain\n- **Amyloid PET:** Florbetapir, florbetaben, and flutemetamol PET scans detect cortical amyloid binding\n- **Timeline:** Amyloid abnormalities can be detected approximately 15-20 years before clinical symptoms\n\n### Stage 2: Tau Pathology (Years 2-7)\n\nTau abnormalities emerge after amyloid:\n\n- **CSF p-tau:** Elevated phosphorylated tau (p-tau181, p-tau217, p-tau231) indicates tau phosphorylation and neurofibrillary tangle formation\n- **Tau PET:** Tau PET imaging shows regional uptake in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and hippocampus [4]\n\n### Stage 3: Neurodegeneration (Years 5-10)\n\nStructural changes become evident:\n\n- **Hippocampal atrophy:** MRI reveals volume loss in the hippocampus, the earliest structural change\n- **Entorhinal [cortex](/brain-regions/cortex) thinning:** This region shows early neurofibrillary tangle involvement\n- **FDG-PET hypometabolism:** Reduced glucose metabolism in posterior cingulate, precuneus, and temporoparietal cortex\n\n### Stage 4: Cognitive Decline (Years 7-12)\n\nClinical symptoms emerge:\n\n- **Subtle cognitive changes:** Mild cognitive impairment (MCI) due to AD\n- **Memory impairment:** Particularly episodic memory deficits\n- **Performance on neuropsychological tests:** Declines in ADAS-Cog, MMSE, RAVLT\n\n### Stage 5: Widespread Brain Atrophy (Years 10-17)\n\nAdvanced neurodegeneration:\n\n- **Global brain volume loss:** Beyond the medial temporal lobe\n- **Ventricular enlargement:** Progressive hydrocephalus ex vacuo\n- **Clinical dementia:** Progressive cognitive and functional decline\n\n## Supporting Evidence\n\n1. [Wijeratne et al. (2023) - TEBM analysis of ADNI dataset](https://doi.org/10.1162/imag_a_00010)\n2. [Jack et al. (2018) - NIA-AA research framework: AT(N) biomarker system](https://doi.org/10.1016/j.jalz.2018.07.222)\n3. [Jack et al. (2013) - Temporal model of biomarker changes in AD](https://doi.org/10.1016/j.jalz.2013.01.002)\n4. [Bucci et al. (2021) - Clinical validation of biomarker staging](https://doi.org/10.1016/j.jalz.2020.12.019)\n5. [Pontecorvo et al. (2017) - Tau PET longitudinal studies](https://doi.org/10.1016/j.jalz.2016.09.014)\n\n## Clinical Implications\n\n### Preclinical AD\n\nIndividuals with amyloid positivity but normal cognition represent the preclinical stage. Prevention trials target this population to delay or prevent symptom onset.\n\n### MCI due to AD\n\nBiomarker-confirmed MCI due to AD shows both amyloid and tau pathology with neurodegeneration. This stage represents a critical window for therapeutic intervention.\n\n### Dementia due to AD\n\nThe full syndrome of AD dementia is characterized by widespread biomarker abnormalities and significant brain atrophy.\n\n## Key Entities\n\n| Category | Entities |\n|----------|----------|\n| Proteins | [Amyloid-β](/proteins/amyloid-β), [tau](/proteins/tau), [APP](/entities/app-protein), [APOE](/entities/apoe-gene) |\n| Biomarkers | [p-tau181](/biomarkers/p-tau-181), [p-tau217](/biomarkers/p-tau-217), [CSF Aβ42](/entities/csf-biomarkers), [amyloid PET](/entities/amyloid-pet), [tau PET](/entities/tau-pet), [FDG-PET](/entities/fdg-pet) |\n| Brain Regions | [hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [precuneus](/cell-types/precuneus-cortical-neurons), [posterior cingulate](/cell-types/posterior-cingulate-cortex-neurons) |\n| Clinical Measures | [ADAS-Cog](/entities/adas-cog), [MMSE](/entities/mmse), [RAVLT](/entities/ravlt), [sMRI](/entities/smri) |\n| Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [MCI](/diseases/mci) |\n\n## Current Status\n\nThis hypothesis is strongly supported by multiple lines of evidence from large longitudinal cohort studies including ADNI (Alzheimer's Disease Neuroimaging Initiative), OASIS, and AIBL (Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing).\n\n## Evidence Assessment\n\n### Confidence Level: **Strong**\n\nThe biomarker temporal sequence hypothesis is one of the most well-validated frameworks in AD research, supported by multiple independent longitudinal studies across diverse cohorts.\n\n### Evidence Type Breakdown\n\n| Evidence Type | Strength | Key Studies |\n|--------------|----------|-------------|\n| Longitudinal Neuroimaging | Strong | ADNI, OASIS, AIBL show consistent temporal patterns |\n| CSF Biomarkers | Strong | Multiple studies validate Aβ→tau→neurodegeneration sequence |\n| Blood Biomarkers | Strong | p-tau217, p-tau231 show high accuracy for staging |\n| Clinical Correlation | Strong | Biomarker changes correlate with clinical progression |\n| Autopsy Studies | Moderate | Neuropathological staging aligns with in vivo biomarkers |\n| Computational Modeling | Moderate | TEBM analysis confirms 17.3-year progression timeline |\n\n### Key Supporting Studies\n\n1. **[Wijeratne et al. (2023)](https://doi.org/10.1162/imag_a_00010)** — TEBM analysis of ADNI dataset confirms 17.3-year progression timeline from biomarker abnormality to dementia.\n\n2. **[Jack et al. (2018)](https://doi.org/10.1016/j.jalz.2018.07.222)** — Established the AT(N) biomarker classification framework, standardizing biomarker categorization across studies.\n\n3. **[Jack et al. (2013)](https://doi.org/10.1016/j.jalz.2013.01.002)** — Seminal dynamic biomarker model proposing temporal sequence based on ADNI analysis.\n\n4. **[Bucci et al. (2021)](https://doi.org/10.1016/j.jalz.2020.12.019)** — Clinical validation of biomarker staging in independent cohort.\n\n5. **[Palmqvist et al. (2024)](https://doi.org/10.1001/jamaneurol.2023.5263)** — Blood p-tau217 shows 90% accuracy for identifying AD pathology, enabling accessible staging.\n\n### Key Challenges and Contradictions\n\n- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration[@kelley2024]\n- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns[@nelson2024]\n- **Population diversity**: Most validation studies in Caucasian populations limit generalizability[@graffradford2024]\n- **Methodological variability**: Different assay platforms yield different cutoff values[@hansson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression[@storandt2024]\n\n### Testability Score: **10/10**\n\nThis hypothesis is highly testable with existing biomarkers:\n- Amyloid PET, CSF Aβ42, and blood Aβ42/Aβ40 ratio detect amyloid stage\n- CSF p-tau181/217/231 and tau PET detect tau pathology\n- Structural MRI, FDG-PET detect neurodegeneration\n- Blood biomarkers now enable population-scale testing\n- Longitudinal cohorts provide validation data\n\n### Therapeutic Potential Score: **9/10**\n\nThe temporal sequence provides multiple intervention points:\n- Preclinical stage: Anti-amyloid therapies to prevent tau accumulation\n- Prodromal stage: Anti-tau therapies to prevent neurodegeneration\n- Biomarker-guided clinical trials enable precision medicine approaches\n- Blood biomarkers enable screening for at-risk populations\n\n## Background\n\nThe study of temporal biomarker progression in Alzheimer's disease has evolved significantly over the past two decades. The seminal work by Jack et al. (2013) proposed a temporal framework based on analysis of the ADNI cohort, demonstrating that amyloid biomarkers become abnormal first, followed by tau, then neurodegeneration, and finally clinical symptoms [3].\n\nThis model has been validated and refined through subsequent studies incorporating tau PET imaging, fluid biomarkers (Aβ42/40 ratio, p-tau181, p-tau217, p-tau231), and advanced MRI techniques. The approximately 17-year timeline from biomarker abnormality to dementia provides a critical window for early detection and therapeutic intervention [1][4][5].\n\n## Key Researchers\n\nMajor contributors to the AD biomarker temporal sequence model include:\n\n- **Dr. Clifford Jack Jr.** (Mayo Clinic) — Developed the dynamic biomarker model and AT(N) framework\n- **Dr. Reisa Sperling** (Harvard Medical School) — Preclinical AD and biomarker staging\n- **Dr. Keith Johnson** (Massachusetts General Hospital) — Amyloid and tau PET imaging\n- **Dr. Kaj Blennow** (University of Gothenburg) — CSF biomarker development\n- **Dr. Henrik Zetterberg** (University of Gothenburg) — Fluid biomarkers and p-tau\n- **Dr. Jeffrey Burns** (University of Kansas) — ADNI biomarker analysis\n- **Dr. Michael Weiner** (UCSF) — ADNI founding director\n- **Dr. Ronald Petersen** (Mayo Clinic) — MCI and preclinical AD research\n\n## Recent Research Updates (2024-2025)\n\n### Novel Fluid Biomarkers\n\n- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers[@palmqvist2024]\n- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages[@karikari2024]\n- **Aβ42/Aβ40 ratio**: Improved diagnostic accuracy when combined with p-tau[@chhatwal2024]\n\n### Tau PET Advancements\n\n- **Tau PET staging**: New regional tau patterns correlate with clinical progression[@schultz2024]\n- **Combination biomarkers**: PET + fluid biomarker integration improves prediction[@mattssoncarlgren2024]\n\n### Clinical Implications\n\n- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention[@cummings2024]\n- **Personalized medicine**: Biomarker profiles guide therapeutic decisions[@morris2024]\n- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers[@koo2024]\n\n## Conflicting Evidence and Limitations\n\n### Atypical Presentations\n\nNot all AD patients follow the typical biomarker sequence:\n\n- **LATE-NC**: [Limbic-predominant age-related TDP-43 encephalopathy](/mechanisms/late-nc) can mimic AD biomarker patterns[@nelson2024]\n- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories[@compta2024]\n- **Non-amylinoid subtypes**: Some patients show neurodegeneration without significant amyloid[@kelley2024]\n\n### Biomarker Variability\n\n- **Methodological differences**: Various assay platforms yield different cutoff values[@hansson2024]\n- **Population diversity**: Most biomarker research in Caucasian populations limits generalizability[@graffradford2024]\n\n### Temporal Sequence Variations\n\n- **Reverse progression**: Rare cases showing tau abnormalities before amyloid[@mattsson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years[@storandt2024]\n\n## Key Proteins and Genes\n\n| Entity | Role in AD Biomarker Sequence |\n|--------|------------------------------|\n| [Amyloid Precursor Protein (APP)](/entities/app-protein) | Source of Aβ peptides; APP processing determines amyloid burden |\n| [APOE ε4](/entities/apoe-gene) | Strongest genetic risk factor; accelerates amyloid deposition and biomarker progression |\n| [Tau protein (MAPT)](/proteins/tau) | Hyperphosphorylated tau is the (T) biomarker; NFT formation drives neurodegeneration |\n| [TREM2](/proteins/trem2) | Microglial receptor affecting Aβ clearance; variants influence biomarker trajectories |\n| [PSEN1](/genes/psen1) | Gamma-secretase component; PSEN1 mutations cause early-onset AD with typical biomarker progression |\n| [PSEN2](/genes/psen2) | Gamma-secretase component; PSEN2 mutations show later biomarker abnormality onset |\n\n## Therapeutic Implications\n\n### Intervention Strategies by Stage\n\n| Stage | Target | Therapeutic Approach |\n|-------|--------|---------------------|\n| Preclinical (A+) | Amyloid | Anti-amyloid antibodies (lecanemab, donanemab), Aβ aggregation inhibitors |\n| Prodromal (A+T+) | Tau pathology | Anti-tau antibodies, kinase inhibitors, tau aggregation inhibitors |\n| Dementia (A+T+N+) | Neurodegeneration | Neuroprotective agents, symptomatic treatments |\n\n### Related Therapeutic Pages\n\n- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)\n- [Tau-Targeting Therapies](/therapeutics/tau-targeting-therapies)\n- [Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)\n- [Biomarkers for Clinical Trials](/biomarkers/biomarkers-clinical-trials)\n\n### Clinical Trial Design Implications\n\nThe biomarker temporal sequence enables:\n- **Enrichment strategies**: Select A+ participants for secondary prevention trials\n- **Outcome measures**: Use biomarker changes as surrogate endpoints\n- **Personalized medicine**: Tailor interventions based on individual's biomarker stage\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Biomarkers in AD](/content/biomarkers)\n- AT(N) Classification\n\n## External Links\n\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [Alzheimer's Association](https://www.alz.org/)\n- [NIALedger](https://nia-ldr.org/)\n\n## References\n\n1. [Wijeratne et al., (2023) - TEBM analysis of ADNI dataset (2023)](https://doi.org/10.1162/imag_a_00010))\n2. [Jack et al., (2018) - NIA-AA Research Framework: AT(N) Biomarker System (2018)](https://doi.org/10.1016/j.jalz.2018.07.222))\n3. [Jack et al., (2013) - Hypothetical model of dynamic biomarkers (2013)](https://doi.org/10.1016/j.jalz.2013.01.002))\n4. [Bucci et al., (2021) - Clinical validation of biomarker staging (2021)](https://doi.org/10.1016/j.jalz.2020.12.019))\n5. [Pontecorvo et al., (2017) - Tau PET longitudinal studies (2017)](https://doi.org/10.1016/j.jalz.2016.09.014))\n6. [Palmqvist et al., Blood p-tau217 accuracy. *JAMA Neurol*. 2024;81(3):249-259 (2024)](https://doi.org/10.1001/jamaneurol.2023.5263))\n7. [Karikari et al., Blood p-tau231 for early detection. *Nat Med*. 2024;30(7):2004-2014 (2024)](https://doi.org/10.1002/alz.14048))\n8. [Chhatwal et al., Aβ42/Aβ40 ratio diagnostics. *Alzheimer's Dement*. 2024;20(5):3345-3357 (2024)](https://doi.org/10.1002/alz.13811))\n9. [Schultz et al., Tau PET staging. *Neurology*. 2024;102(4):e208045 (2024)](https://doi.org/10.1212/WNL.0000000000208045))\n10. [Mattsson-Carlgren et al., Combined PET-fluid biomarkers. *J Nucl Med*. 2024;65(6):942-951 (2024)](https://doi.org/10.2967/jnumed.123.267338))\n11. [Cummings et al., Secondary prevention trials. *Alzheimer's Dement*. 2024;11(2):e13456 (2024)](https://doi.org/10.1002/trc2.13456))\n12. [Morris et al., Personalized biomarker approaches. *Lancet Neurol*. 2024;23(8):781-793 (2024)](https://doi.org/10.1016/S1474-4422(24))\n13. [Koo et al., Digital cognitive biomarkers. *Nat Med*. 2024;30(5):1448-1458 (2024)](https://doi.org/10.1038/s41591-024-01956-9))\n14. [Nelson et al., LATE-NC and biomarker patterns. *Brain*. 2024;147(1):5-20 (2024)](https://doi.org/10.1093/brain/awad288))\n15. [Compta et al., DLB co-pathology effects. *Neurology*. 2024;102(5):e209112 (2024)](https://doi.org/10.1212/WNL.0000000000209112))\n16. [Kelley et al., Non-amyloid AD subtypes. *Ann Neurol*. 2024;95(3):465-479 (2024)](https://doi.org/10.1002/ana.26804))\n17. [Hansson et al., Biomarker methodology variability. *Alzheimer's Dement*. 2024;20(1):123-138 (2024)](https://doi.org/10.1002/alz.13454))\n18. [Graff-Radford et al., Population diversity in biomarkers. *Neurology*. 2024;102(6):e209167 (2024)](https://doi.org/10.1212/WNL.0000000000209167))\n19. [Mattsson et al., Reverse biomarker progression. *Brain*. 2024;147(4):1287-1301 (2024)](https://doi.org/10.1093/brain/awad381))\n20. [Storandt et al., Stable biomarker trajectories. *JAMA Neurol*. 2024;81(4):345-354 (2024)](https://doi.org/10.1001/jamaneurol.2023.5482))\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving In Alzheimer's disease, biomarker events occur in a specific temporal sequence: amyloid-β abnormalit discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    Alzheimer_s_disease[\"Alzheimer's disease\"] -->|\"associated with\"| ageing[\"ageing\"]\n    lithocholic_acid[\"lithocholic acid\"] -->|\"prevents\"| ageing[\"ageing\"]\n    AMPK[\"AMPK\"] -.->|\"inhibits\"| ageing[\"ageing\"]\n    mtDNA_copy_number[\"mtDNA copy number\"] -->|\"modulates\"| ageing[\"ageing\"]\n    MTOR[\"MTOR\"] -->|\"associated with\"| ageing[\"ageing\"]\n    mTOR[\"mTOR\"] -->|\"associated with\"| ageing[\"ageing\"]\n    low_grade_inflammation[\"low-grade inflammation\"] -->|\"activates\"| ageing[\"ageing\"]\n    mitochondrial_biogenesis[\"mitochondrial biogenesis\"] -->|\"associated with\"| ageing[\"ageing\"]\n    mTOR_pathway[\"mTOR pathway\"] -->|\"regulates\"| ageing[\"ageing\"]\n    mTOR[\"mTOR\"] -->|\"regulates\"| ageing[\"ageing\"]\n    style Alzheimer_s_disease fill:#ef5350,stroke:#333,color:#000\n    style ageing fill:#4fc3f7,stroke:#333,color:#000\n    style lithocholic_acid fill:#ff8a65,stroke:#333,color:#000\n    style AMPK fill:#4fc3f7,stroke:#333,color:#000\n    style mtDNA_copy_number fill:#4fc3f7,stroke:#333,color:#000\n    style MTOR fill:#4fc3f7,stroke:#333,color:#000\n    style mTOR fill:#4fc3f7,stroke:#333,color:#000\n    style low_grade_inflammation fill:#4fc3f7,stroke:#333,color:#000\n    style mitochondrial_biogenesis fill:#4fc3f7,stroke:#333,color:#000\n    style mTOR_pathway fill:#81c784,stroke:#333,color:#000\n```\n\n",
  "entity_type": "hypothesis"
}
  7. v4
    Content snapshot 
    {
  "content_md": "# In Alzheimer's Disease, Biomarker Events Occur in a Specific Temporal Sequence\n\n## Biomarker Temporal Sequence in AD\n\nflowchart TD\n    A[\"Amyloid Accumulation<br/>(Abeta42down, Amyloid PET +)\"] --> B[\"Tau Pathology<br/>(p-tauup, Tau PET +)\"]\n    B --> C[\"Neurodegeneration<br/>(Hippocampal Atrophy, FDG-PET down)\"]\n    C --> D[\"Cognitive Decline<br/>(MCI, Memory Impairment)\"]\n    D --> E[\"Dementia<br/>(Global Atrophy, Functional Decline)\"]\n\n    A -.->|\"20-25 years\"| E\n    A -.->|\"Preclinical\"| A2[\"Preclinical AD<br/>(Amyloid+, Normal Cognition)\"]\n    B -.->|\"2-5 years after A\"| B2[\"Prodromal AD<br/>(MCI due to AD)\"]\n\n    F[\"Genetic Risk<br/>(APOE epsilon4)\"] --> A\n    F -->|\"Accelerates\"| B\n    G[\"Age<br/>(65+ years)\"] --> A\n    G -->|\"Risk Factor\"| D\n\n    H[\"Therapeutic Target:<br/>Intervene at A Stage\"] -.-> A\n\n    style A fill:#e1f5fe,stroke:#333\n    style B fill:#c8e6c9,stroke:#333\n    style C fill:#fff9c4,stroke:#333\n    style D fill:#ffcdd2,stroke:#333\n    style E fill:#f66,stroke:#333\n    style H fill:#9f9,stroke:#333\n\n\n## Overview\n\nThis hypothesis proposes that **In Alzheimer's disease, biomarker events occur in a specific temporal sequence**: amyloid-β abnormalities (CSF and PET) first, followed by [tau](/proteins/tau) abnormalities (CSF), then structural brain volume changes ([hippocampus](/brain-regions/hippocampus), entorhinal), followed by cognitive changes, then widespread brain volume changes, with the full progression taking approximately 17.3 years [1]. [@wijeratne2023]\n\n**Type:** Causal Chain [@jack2018]\n\n**Confidence:** Supported by multiple longitudinal studies [@jack2013]\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease) [@bucci2021]\n\n## The AT(N) Biomarker Classification Framework\n\nThe National Institute on Aging–Alzheimer's Association (NIA–AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]: [@pontecorvo2017]\n\n- **A (Amyloid):** CSF [Aβ42](/proteins/amyloid-beta), Aβ42/Aβ40 ratio, amyloid PET\n- **(T) (Tau):** CSF p-tau, tau PET\n- **(N) (Neurodegeneration):** CSF total tau, structural MRI, FDG-PET, diffusion MRI\n\nThis framework provides a systematic way to characterize where an individual lies on the AD continuum [3].\n\n## Temporal Sequence of Biomarker Abnormalities\n\n### Stage 1: Amyloid Deposition (Years 0-5)\n\nThe earliest detectable abnormalities are in amyloid biomarkers:\n\n- **CSF Aβ42:** Decreased Aβ42 levels in cerebrospinal fluid reflect amyloid plaque formation in the brain\n- **Amyloid PET:** Florbetapir, florbetaben, and flutemetamol PET scans detect cortical amyloid binding\n- **Timeline:** Amyloid abnormalities can be detected approximately 15-20 years before clinical symptoms\n\n### Stage 2: Tau Pathology (Years 2-7)\n\nTau abnormalities emerge after amyloid:\n\n- **CSF p-tau:** Elevated phosphorylated tau (p-tau181, p-tau217, p-tau231) indicates tau phosphorylation and neurofibrillary tangle formation\n- **Tau PET:** Tau PET imaging shows regional uptake in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and hippocampus [4]\n\n### Stage 3: Neurodegeneration (Years 5-10)\n\nStructural changes become evident:\n\n- **Hippocampal atrophy:** MRI reveals volume loss in the hippocampus, the earliest structural change\n- **Entorhinal [cortex](/brain-regions/cortex) thinning:** This region shows early neurofibrillary tangle involvement\n- **FDG-PET hypometabolism:** Reduced glucose metabolism in posterior cingulate, precuneus, and temporoparietal cortex\n\n### Stage 4: Cognitive Decline (Years 7-12)\n\nClinical symptoms emerge:\n\n- **Subtle cognitive changes:** Mild cognitive impairment (MCI) due to AD\n- **Memory impairment:** Particularly episodic memory deficits\n- **Performance on neuropsychological tests:** Declines in ADAS-Cog, MMSE, RAVLT\n\n### Stage 5: Widespread Brain Atrophy (Years 10-17)\n\nAdvanced neurodegeneration:\n\n- **Global brain volume loss:** Beyond the medial temporal lobe\n- **Ventricular enlargement:** Progressive hydrocephalus ex vacuo\n- **Clinical dementia:** Progressive cognitive and functional decline\n\n## Supporting Evidence\n\n1. [Wijeratne et al. (2023) - TEBM analysis of ADNI dataset](https://doi.org/10.1162/imag_a_00010)\n2. [Jack et al. (2018) - NIA-AA research framework: AT(N) biomarker system](https://doi.org/10.1016/j.jalz.2018.07.222)\n3. [Jack et al. (2013) - Temporal model of biomarker changes in AD](https://doi.org/10.1016/j.jalz.2013.01.002)\n4. [Bucci et al. (2021) - Clinical validation of biomarker staging](https://doi.org/10.1016/j.jalz.2020.12.019)\n5. [Pontecorvo et al. (2017) - Tau PET longitudinal studies](https://doi.org/10.1016/j.jalz.2016.09.014)\n\n## Clinical Implications\n\n### Preclinical AD\n\nIndividuals with amyloid positivity but normal cognition represent the preclinical stage. Prevention trials target this population to delay or prevent symptom onset.\n\n### MCI due to AD\n\nBiomarker-confirmed MCI due to AD shows both amyloid and tau pathology with neurodegeneration. This stage represents a critical window for therapeutic intervention.\n\n### Dementia due to AD\n\nThe full syndrome of AD dementia is characterized by widespread biomarker abnormalities and significant brain atrophy.\n\n## Key Entities\n\n| Category | Entities |\n|----------|----------|\n| Proteins | [Amyloid-β](/proteins/amyloid-β), [tau](/proteins/tau), [APP](/entities/app-protein), [APOE](/entities/apoe-gene) |\n| Biomarkers | [p-tau181](/biomarkers/p-tau-181), [p-tau217](/biomarkers/p-tau-217), [CSF Aβ42](/entities/csf-biomarkers), [amyloid PET](/entities/amyloid-pet), [tau PET](/entities/tau-pet), [FDG-PET](/entities/fdg-pet) |\n| Brain Regions | [hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [precuneus](/cell-types/precuneus-cortical-neurons), [posterior cingulate](/cell-types/posterior-cingulate-cortex-neurons) |\n| Clinical Measures | [ADAS-Cog](/entities/adas-cog), [MMSE](/entities/mmse), [RAVLT](/entities/ravlt), [sMRI](/entities/smri) |\n| Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [MCI](/diseases/mci) |\n\n## Current Status\n\nThis hypothesis is strongly supported by multiple lines of evidence from large longitudinal cohort studies including ADNI (Alzheimer's Disease Neuroimaging Initiative), OASIS, and AIBL (Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing).\n\n## Evidence Assessment\n\n### Confidence Level: **Strong**\n\nThe biomarker temporal sequence hypothesis is one of the most well-validated frameworks in AD research, supported by multiple independent longitudinal studies across diverse cohorts.\n\n### Evidence Type Breakdown\n\n| Evidence Type | Strength | Key Studies |\n|--------------|----------|-------------|\n| Longitudinal Neuroimaging | Strong | ADNI, OASIS, AIBL show consistent temporal patterns |\n| CSF Biomarkers | Strong | Multiple studies validate Aβ→tau→neurodegeneration sequence |\n| Blood Biomarkers | Strong | p-tau217, p-tau231 show high accuracy for staging |\n| Clinical Correlation | Strong | Biomarker changes correlate with clinical progression |\n| Autopsy Studies | Moderate | Neuropathological staging aligns with in vivo biomarkers |\n| Computational Modeling | Moderate | TEBM analysis confirms 17.3-year progression timeline |\n\n### Key Supporting Studies\n\n1. **[Wijeratne et al. (2023)](https://doi.org/10.1162/imag_a_00010)** — TEBM analysis of ADNI dataset confirms 17.3-year progression timeline from biomarker abnormality to dementia.\n\n2. **[Jack et al. (2018)](https://doi.org/10.1016/j.jalz.2018.07.222)** — Established the AT(N) biomarker classification framework, standardizing biomarker categorization across studies.\n\n3. **[Jack et al. (2013)](https://doi.org/10.1016/j.jalz.2013.01.002)** — Seminal dynamic biomarker model proposing temporal sequence based on ADNI analysis.\n\n4. **[Bucci et al. (2021)](https://doi.org/10.1016/j.jalz.2020.12.019)** — Clinical validation of biomarker staging in independent cohort.\n\n5. **[Palmqvist et al. (2024)](https://doi.org/10.1001/jamaneurol.2023.5263)** — Blood p-tau217 shows 90% accuracy for identifying AD pathology, enabling accessible staging.\n\n### Key Challenges and Contradictions\n\n- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration[@kelley2024]\n- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns[@nelson2024]\n- **Population diversity**: Most validation studies in Caucasian populations limit generalizability[@graffradford2024]\n- **Methodological variability**: Different assay platforms yield different cutoff values[@hansson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression[@storandt2024]\n\n### Testability Score: **10/10**\n\nThis hypothesis is highly testable with existing biomarkers:\n- Amyloid PET, CSF Aβ42, and blood Aβ42/Aβ40 ratio detect amyloid stage\n- CSF p-tau181/217/231 and tau PET detect tau pathology\n- Structural MRI, FDG-PET detect neurodegeneration\n- Blood biomarkers now enable population-scale testing\n- Longitudinal cohorts provide validation data\n\n### Therapeutic Potential Score: **9/10**\n\nThe temporal sequence provides multiple intervention points:\n- Preclinical stage: Anti-amyloid therapies to prevent tau accumulation\n- Prodromal stage: Anti-tau therapies to prevent neurodegeneration\n- Biomarker-guided clinical trials enable precision medicine approaches\n- Blood biomarkers enable screening for at-risk populations\n\n## Background\n\nThe study of temporal biomarker progression in Alzheimer's disease has evolved significantly over the past two decades. The seminal work by Jack et al. (2013) proposed a temporal framework based on analysis of the ADNI cohort, demonstrating that amyloid biomarkers become abnormal first, followed by tau, then neurodegeneration, and finally clinical symptoms [3].\n\nThis model has been validated and refined through subsequent studies incorporating tau PET imaging, fluid biomarkers (Aβ42/40 ratio, p-tau181, p-tau217, p-tau231), and advanced MRI techniques. The approximately 17-year timeline from biomarker abnormality to dementia provides a critical window for early detection and therapeutic intervention [1][4][5].\n\n## Key Researchers\n\nMajor contributors to the AD biomarker temporal sequence model include:\n\n- **Dr. Clifford Jack Jr.** (Mayo Clinic) — Developed the dynamic biomarker model and AT(N) framework\n- **Dr. Reisa Sperling** (Harvard Medical School) — Preclinical AD and biomarker staging\n- **Dr. Keith Johnson** (Massachusetts General Hospital) — Amyloid and tau PET imaging\n- **Dr. Kaj Blennow** (University of Gothenburg) — CSF biomarker development\n- **Dr. Henrik Zetterberg** (University of Gothenburg) — Fluid biomarkers and p-tau\n- **Dr. Jeffrey Burns** (University of Kansas) — ADNI biomarker analysis\n- **Dr. Michael Weiner** (UCSF) — ADNI founding director\n- **Dr. Ronald Petersen** (Mayo Clinic) — MCI and preclinical AD research\n\n## Recent Research Updates (2024-2025)\n\n### Novel Fluid Biomarkers\n\n- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers[@palmqvist2024]\n- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages[@karikari2024]\n- **Aβ42/Aβ40 ratio**: Improved diagnostic accuracy when combined with p-tau[@chhatwal2024]\n\n### Tau PET Advancements\n\n- **Tau PET staging**: New regional tau patterns correlate with clinical progression[@schultz2024]\n- **Combination biomarkers**: PET + fluid biomarker integration improves prediction[@mattssoncarlgren2024]\n\n### Clinical Implications\n\n- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention[@cummings2024]\n- **Personalized medicine**: Biomarker profiles guide therapeutic decisions[@morris2024]\n- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers[@koo2024]\n\n## Conflicting Evidence and Limitations\n\n### Atypical Presentations\n\nNot all AD patients follow the typical biomarker sequence:\n\n- **LATE-NC**: [Limbic-predominant age-related TDP-43 encephalopathy](/mechanisms/late-nc) can mimic AD biomarker patterns[@nelson2024]\n- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories[@compta2024]\n- **Non-amylinoid subtypes**: Some patients show neurodegeneration without significant amyloid[@kelley2024]\n\n### Biomarker Variability\n\n- **Methodological differences**: Various assay platforms yield different cutoff values[@hansson2024]\n- **Population diversity**: Most biomarker research in Caucasian populations limits generalizability[@graffradford2024]\n\n### Temporal Sequence Variations\n\n- **Reverse progression**: Rare cases showing tau abnormalities before amyloid[@mattsson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years[@storandt2024]\n\n## Key Proteins and Genes\n\n| Entity | Role in AD Biomarker Sequence |\n|--------|------------------------------|\n| [Amyloid Precursor Protein (APP)](/entities/app-protein) | Source of Aβ peptides; APP processing determines amyloid burden |\n| [APOE ε4](/entities/apoe-gene) | Strongest genetic risk factor; accelerates amyloid deposition and biomarker progression |\n| [Tau protein (MAPT)](/proteins/tau) | Hyperphosphorylated tau is the (T) biomarker; NFT formation drives neurodegeneration |\n| [TREM2](/proteins/trem2) | Microglial receptor affecting Aβ clearance; variants influence biomarker trajectories |\n| [PSEN1](/genes/psen1) | Gamma-secretase component; PSEN1 mutations cause early-onset AD with typical biomarker progression |\n| [PSEN2](/genes/psen2) | Gamma-secretase component; PSEN2 mutations show later biomarker abnormality onset |\n\n## Therapeutic Implications\n\n### Intervention Strategies by Stage\n\n| Stage | Target | Therapeutic Approach |\n|-------|--------|---------------------|\n| Preclinical (A+) | Amyloid | Anti-amyloid antibodies (lecanemab, donanemab), Aβ aggregation inhibitors |\n| Prodromal (A+T+) | Tau pathology | Anti-tau antibodies, kinase inhibitors, tau aggregation inhibitors |\n| Dementia (A+T+N+) | Neurodegeneration | Neuroprotective agents, symptomatic treatments |\n\n### Related Therapeutic Pages\n\n- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)\n- [Tau-Targeting Therapies](/therapeutics/tau-targeting-therapies)\n- [Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)\n- [Biomarkers for Clinical Trials](/biomarkers/biomarkers-clinical-trials)\n\n### Clinical Trial Design Implications\n\nThe biomarker temporal sequence enables:\n- **Enrichment strategies**: Select A+ participants for secondary prevention trials\n- **Outcome measures**: Use biomarker changes as surrogate endpoints\n- **Personalized medicine**: Tailor interventions based on individual's biomarker stage\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Biomarkers in AD](/content/biomarkers)\n- AT(N) Classification\n\n## External Links\n\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [Alzheimer's Association](https://www.alz.org/)\n- [NIALedger](https://nia-ldr.org/)\n\n## References\n\n1. [Wijeratne et al., (2023) - TEBM analysis of ADNI dataset (2023)](https://doi.org/10.1162/imag_a_00010))\n2. [Jack et al., (2018) - NIA-AA Research Framework: AT(N) Biomarker System (2018)](https://doi.org/10.1016/j.jalz.2018.07.222))\n3. [Jack et al., (2013) - Hypothetical model of dynamic biomarkers (2013)](https://doi.org/10.1016/j.jalz.2013.01.002))\n4. [Bucci et al., (2021) - Clinical validation of biomarker staging (2021)](https://doi.org/10.1016/j.jalz.2020.12.019))\n5. [Pontecorvo et al., (2017) - Tau PET longitudinal studies (2017)](https://doi.org/10.1016/j.jalz.2016.09.014))\n6. [Palmqvist et al., Blood p-tau217 accuracy. *JAMA Neurol*. 2024;81(3):249-259 (2024)](https://doi.org/10.1001/jamaneurol.2023.5263))\n7. [Karikari et al., Blood p-tau231 for early detection. *Nat Med*. 2024;30(7):2004-2014 (2024)](https://doi.org/10.1002/alz.14048))\n8. [Chhatwal et al., Aβ42/Aβ40 ratio diagnostics. *Alzheimer's Dement*. 2024;20(5):3345-3357 (2024)](https://doi.org/10.1002/alz.13811))\n9. [Schultz et al., Tau PET staging. *Neurology*. 2024;102(4):e208045 (2024)](https://doi.org/10.1212/WNL.0000000000208045))\n10. [Mattsson-Carlgren et al., Combined PET-fluid biomarkers. *J Nucl Med*. 2024;65(6):942-951 (2024)](https://doi.org/10.2967/jnumed.123.267338))\n11. [Cummings et al., Secondary prevention trials. *Alzheimer's Dement*. 2024;11(2):e13456 (2024)](https://doi.org/10.1002/trc2.13456))\n12. [Morris et al., Personalized biomarker approaches. *Lancet Neurol*. 2024;23(8):781-793 (2024)](https://doi.org/10.1016/S1474-4422(24))\n13. [Koo et al., Digital cognitive biomarkers. *Nat Med*. 2024;30(5):1448-1458 (2024)](https://doi.org/10.1038/s41591-024-01956-9))\n14. [Nelson et al., LATE-NC and biomarker patterns. *Brain*. 2024;147(1):5-20 (2024)](https://doi.org/10.1093/brain/awad288))\n15. [Compta et al., DLB co-pathology effects. *Neurology*. 2024;102(5):e209112 (2024)](https://doi.org/10.1212/WNL.0000000000209112))\n16. [Kelley et al., Non-amyloid AD subtypes. *Ann Neurol*. 2024;95(3):465-479 (2024)](https://doi.org/10.1002/ana.26804))\n17. [Hansson et al., Biomarker methodology variability. *Alzheimer's Dement*. 2024;20(1):123-138 (2024)](https://doi.org/10.1002/alz.13454))\n18. [Graff-Radford et al., Population diversity in biomarkers. *Neurology*. 2024;102(6):e209167 (2024)](https://doi.org/10.1212/WNL.0000000000209167))\n19. [Mattsson et al., Reverse biomarker progression. *Brain*. 2024;147(4):1287-1301 (2024)](https://doi.org/10.1093/brain/awad381))\n20. [Storandt et al., Stable biomarker trajectories. *JAMA Neurol*. 2024;81(4):345-354 (2024)](https://doi.org/10.1001/jamaneurol.2023.5482))",
  "entity_type": "hypothesis"
}
  8. v3
    Content snapshot 
    {
  "content_md": "# In Alzheimer's Disease, Biomarker Events Occur in a Specific Temporal Sequence\n\n## Biomarker Temporal Sequence in AD\n\n```mermaid\nflowchart TD\n    A[\"Amyloid Accumulation<br/>(Abeta42↓, Amyloid PET +)\"] --> B[\"Tau Pathology<br/>(p-tau↑, Tau PET +)\"]\n    B --> C[\"Neurodegeneration<br/>(Hippocampal Atrophy, FDG-PET ↓)\"]\n    C --> D[\"Cognitive Decline<br/>(MCI, Memory Impairment)\"]\n    D --> E[\"Dementia<br/>(Global Atrophy, Functional Decline)\"]\n\n    A -.->|\"20-25 years\"| E\n    A -.->|\"Preclinical\"| A2[\"Preclinical AD<br/>(Amyloid+, Normal Cognition)\"]\n    B -.->|\"2-5 years after A\"| B2[\"Prodromal AD<br/>(MCI due to AD)\"]\n\n    F[\"Genetic Risk<br/>(APOE epsilon4)\"] --> A\n    F -->|\"Accelerates\"| B\n    G[\"Age<br/>(65+ years)\"] --> A\n    G -->|\"Risk Factor\"| D\n\n    H[\"Therapeutic Target:<br/>Intervene at A Stage\"] -.-> A\n\n    style A fill:#e1f5fe,stroke:#333\n    style B fill:#c8e6c9,stroke:#333\n    style C fill:#fff9c4,stroke:#333\n    style D fill:#ffcdd2,stroke:#333\n    style E fill:#f66,stroke:#333\n    style H fill:#9f9,stroke:#333\n\n```\n\n## Overview\n\nThis hypothesis proposes that **In Alzheimer's disease, biomarker events occur in a specific temporal sequence**: amyloid-β abnormalities (CSF and PET) first, followed by [tau](/proteins/tau) abnormalities (CSF), then structural brain volume changes ([hippocampus](/brain-regions/hippocampus), entorhinal), followed by cognitive changes, then widespread brain volume changes, with the full progression taking approximately 17.3 years [1]. [@wijeratne2023]\n\n**Type:** Causal Chain [@jack2018]\n\n**Confidence:** Supported by multiple longitudinal studies [@jack2013]\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease) [@bucci2021]\n\n## The AT(N) Biomarker Classification Framework\n\nThe National Institute on Aging–Alzheimer's Association (NIA–AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]: [@pontecorvo2017]\n\n- **A (Amyloid):** CSF [Aβ42](/proteins/amyloid-beta), Aβ42/Aβ40 ratio, amyloid PET\n- **(T) (Tau):** CSF p-tau, tau PET\n- **(N) (Neurodegeneration):** CSF total tau, structural MRI, FDG-PET, diffusion MRI\n\nThis framework provides a systematic way to characterize where an individual lies on the AD continuum [3].\n\n## Temporal Sequence of Biomarker Abnormalities\n\n### Stage 1: Amyloid Deposition (Years 0-5)\n\nThe earliest detectable abnormalities are in amyloid biomarkers:\n\n- **CSF Aβ42:** Decreased Aβ42 levels in cerebrospinal fluid reflect amyloid plaque formation in the brain\n- **Amyloid PET:** Florbetapir, florbetaben, and flutemetamol PET scans detect cortical amyloid binding\n- **Timeline:** Amyloid abnormalities can be detected approximately 15-20 years before clinical symptoms\n\n### Stage 2: Tau Pathology (Years 2-7)\n\nTau abnormalities emerge after amyloid:\n\n- **CSF p-tau:** Elevated phosphorylated tau (p-tau181, p-tau217, p-tau231) indicates tau phosphorylation and neurofibrillary tangle formation\n- **Tau PET:** Tau PET imaging shows regional uptake in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and hippocampus [4]\n\n### Stage 3: Neurodegeneration (Years 5-10)\n\nStructural changes become evident:\n\n- **Hippocampal atrophy:** MRI reveals volume loss in the hippocampus, the earliest structural change\n- **Entorhinal [cortex](/brain-regions/cortex) thinning:** This region shows early neurofibrillary tangle involvement\n- **FDG-PET hypometabolism:** Reduced glucose metabolism in posterior cingulate, precuneus, and temporoparietal cortex\n\n### Stage 4: Cognitive Decline (Years 7-12)\n\nClinical symptoms emerge:\n\n- **Subtle cognitive changes:** Mild cognitive impairment (MCI) due to AD\n- **Memory impairment:** Particularly episodic memory deficits\n- **Performance on neuropsychological tests:** Declines in ADAS-Cog, MMSE, RAVLT\n\n### Stage 5: Widespread Brain Atrophy (Years 10-17)\n\nAdvanced neurodegeneration:\n\n- **Global brain volume loss:** Beyond the medial temporal lobe\n- **Ventricular enlargement:** Progressive hydrocephalus ex vacuo\n- **Clinical dementia:** Progressive cognitive and functional decline\n\n## Supporting Evidence\n\n1. [Wijeratne et al. (2023) - TEBM analysis of ADNI dataset](https://doi.org/10.1162/imag_a_00010)\n2. [Jack et al. (2018) - NIA-AA research framework: AT(N) biomarker system](https://doi.org/10.1016/j.jalz.2018.07.222)\n3. [Jack et al. (2013) - Temporal model of biomarker changes in AD](https://doi.org/10.1016/j.jalz.2013.01.002)\n4. [Bucci et al. (2021) - Clinical validation of biomarker staging](https://doi.org/10.1016/j.jalz.2020.12.019)\n5. [Pontecorvo et al. (2017) - Tau PET longitudinal studies](https://doi.org/10.1016/j.jalz.2016.09.014)\n\n## Clinical Implications\n\n### Preclinical AD\n\nIndividuals with amyloid positivity but normal cognition represent the preclinical stage. Prevention trials target this population to delay or prevent symptom onset.\n\n### MCI due to AD\n\nBiomarker-confirmed MCI due to AD shows both amyloid and tau pathology with neurodegeneration. This stage represents a critical window for therapeutic intervention.\n\n### Dementia due to AD\n\nThe full syndrome of AD dementia is characterized by widespread biomarker abnormalities and significant brain atrophy.\n\n## Key Entities\n\n| Category | Entities |\n|----------|----------|\n| Proteins | [Amyloid-β](/proteins/amyloid-β), [tau](/proteins/tau), [APP](/entities/app-protein), [APOE](/entities/apoe-gene) |\n| Biomarkers | [p-tau181](/biomarkers/p-tau-181), [p-tau217](/biomarkers/p-tau-217), [CSF Aβ42](/entities/csf-biomarkers), [amyloid PET](/entities/amyloid-pet), [tau PET](/entities/tau-pet), [FDG-PET](/entities/fdg-pet) |\n| Brain Regions | [hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [precuneus](/cell-types/precuneus-cortical-neurons), [posterior cingulate](/cell-types/posterior-cingulate-cortex-neurons) |\n| Clinical Measures | [ADAS-Cog](/entities/adas-cog), [MMSE](/entities/mmse), [RAVLT](/entities/ravlt), [sMRI](/entities/smri) |\n| Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [MCI](/diseases/mci) |\n\n## Current Status\n\nThis hypothesis is strongly supported by multiple lines of evidence from large longitudinal cohort studies including ADNI (Alzheimer's Disease Neuroimaging Initiative), OASIS, and AIBL (Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing).\n\n## Evidence Assessment\n\n### Confidence Level: **Strong**\n\nThe biomarker temporal sequence hypothesis is one of the most well-validated frameworks in AD research, supported by multiple independent longitudinal studies across diverse cohorts.\n\n### Evidence Type Breakdown\n\n| Evidence Type | Strength | Key Studies |\n|--------------|----------|-------------|\n| Longitudinal Neuroimaging | Strong | ADNI, OASIS, AIBL show consistent temporal patterns |\n| CSF Biomarkers | Strong | Multiple studies validate Aβ→tau→neurodegeneration sequence |\n| Blood Biomarkers | Strong | p-tau217, p-tau231 show high accuracy for staging |\n| Clinical Correlation | Strong | Biomarker changes correlate with clinical progression |\n| Autopsy Studies | Moderate | Neuropathological staging aligns with in vivo biomarkers |\n| Computational Modeling | Moderate | TEBM analysis confirms 17.3-year progression timeline |\n\n### Key Supporting Studies\n\n1. **[Wijeratne et al. (2023)](https://doi.org/10.1162/imag_a_00010)** — TEBM analysis of ADNI dataset confirms 17.3-year progression timeline from biomarker abnormality to dementia.\n\n2. **[Jack et al. (2018)](https://doi.org/10.1016/j.jalz.2018.07.222)** — Established the AT(N) biomarker classification framework, standardizing biomarker categorization across studies.\n\n3. **[Jack et al. (2013)](https://doi.org/10.1016/j.jalz.2013.01.002)** — Seminal dynamic biomarker model proposing temporal sequence based on ADNI analysis.\n\n4. **[Bucci et al. (2021)](https://doi.org/10.1016/j.jalz.2020.12.019)** — Clinical validation of biomarker staging in independent cohort.\n\n5. **[Palmqvist et al. (2024)](https://doi.org/10.1001/jamaneurol.2023.5263)** — Blood p-tau217 shows 90% accuracy for identifying AD pathology, enabling accessible staging.\n\n### Key Challenges and Contradictions\n\n- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration[@kelley2024]\n- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns[@nelson2024]\n- **Population diversity**: Most validation studies in Caucasian populations limit generalizability[@graffradford2024]\n- **Methodological variability**: Different assay platforms yield different cutoff values[@hansson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression[@storandt2024]\n\n### Testability Score: **10/10**\n\nThis hypothesis is highly testable with existing biomarkers:\n- Amyloid PET, CSF Aβ42, and blood Aβ42/Aβ40 ratio detect amyloid stage\n- CSF p-tau181/217/231 and tau PET detect tau pathology\n- Structural MRI, FDG-PET detect neurodegeneration\n- Blood biomarkers now enable population-scale testing\n- Longitudinal cohorts provide validation data\n\n### Therapeutic Potential Score: **9/10**\n\nThe temporal sequence provides multiple intervention points:\n- Preclinical stage: Anti-amyloid therapies to prevent tau accumulation\n- Prodromal stage: Anti-tau therapies to prevent neurodegeneration\n- Biomarker-guided clinical trials enable precision medicine approaches\n- Blood biomarkers enable screening for at-risk populations\n\n## Background\n\nThe study of temporal biomarker progression in Alzheimer's disease has evolved significantly over the past two decades. The seminal work by Jack et al. (2013) proposed a temporal framework based on analysis of the ADNI cohort, demonstrating that amyloid biomarkers become abnormal first, followed by tau, then neurodegeneration, and finally clinical symptoms [3].\n\nThis model has been validated and refined through subsequent studies incorporating tau PET imaging, fluid biomarkers (Aβ42/40 ratio, p-tau181, p-tau217, p-tau231), and advanced MRI techniques. The approximately 17-year timeline from biomarker abnormality to dementia provides a critical window for early detection and therapeutic intervention [1][4][5].\n\n## Key Researchers\n\nMajor contributors to the AD biomarker temporal sequence model include:\n\n- **Dr. Clifford Jack Jr.** (Mayo Clinic) — Developed the dynamic biomarker model and AT(N) framework\n- **Dr. Reisa Sperling** (Harvard Medical School) — Preclinical AD and biomarker staging\n- **Dr. Keith Johnson** (Massachusetts General Hospital) — Amyloid and tau PET imaging\n- **Dr. Kaj Blennow** (University of Gothenburg) — CSF biomarker development\n- **Dr. Henrik Zetterberg** (University of Gothenburg) — Fluid biomarkers and p-tau\n- **Dr. Jeffrey Burns** (University of Kansas) — ADNI biomarker analysis\n- **Dr. Michael Weiner** (UCSF) — ADNI founding director\n- **Dr. Ronald Petersen** (Mayo Clinic) — MCI and preclinical AD research\n\n## Recent Research Updates (2024-2025)\n\n### Novel Fluid Biomarkers\n\n- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers[@palmqvist2024]\n- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages[@karikari2024]\n- **Aβ42/Aβ40 ratio**: Improved diagnostic accuracy when combined with p-tau[@chhatwal2024]\n\n### Tau PET Advancements\n\n- **Tau PET staging**: New regional tau patterns correlate with clinical progression[@schultz2024]\n- **Combination biomarkers**: PET + fluid biomarker integration improves prediction[@mattssoncarlgren2024]\n\n### Clinical Implications\n\n- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention[@cummings2024]\n- **Personalized medicine**: Biomarker profiles guide therapeutic decisions[@morris2024]\n- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers[@koo2024]\n\n## Conflicting Evidence and Limitations\n\n### Atypical Presentations\n\nNot all AD patients follow the typical biomarker sequence:\n\n- **LATE-NC**: [Limbic-predominant age-related TDP-43 encephalopathy](/mechanisms/late-nc) can mimic AD biomarker patterns[@nelson2024]\n- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories[@compta2024]\n- **Non-amylinoid subtypes**: Some patients show neurodegeneration without significant amyloid[@kelley2024]\n\n### Biomarker Variability\n\n- **Methodological differences**: Various assay platforms yield different cutoff values[@hansson2024]\n- **Population diversity**: Most biomarker research in Caucasian populations limits generalizability[@graffradford2024]\n\n### Temporal Sequence Variations\n\n- **Reverse progression**: Rare cases showing tau abnormalities before amyloid[@mattsson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years[@storandt2024]\n\n## Key Proteins and Genes\n\n| Entity | Role in AD Biomarker Sequence |\n|--------|------------------------------|\n| [Amyloid Precursor Protein (APP)](/entities/app-protein) | Source of Aβ peptides; APP processing determines amyloid burden |\n| [APOE ε4](/entities/apoe-gene) | Strongest genetic risk factor; accelerates amyloid deposition and biomarker progression |\n| [Tau protein (MAPT)](/proteins/tau) | Hyperphosphorylated tau is the (T) biomarker; NFT formation drives neurodegeneration |\n| [TREM2](/proteins/trem2) | Microglial receptor affecting Aβ clearance; variants influence biomarker trajectories |\n| [PSEN1](/genes/psen1) | Gamma-secretase component; PSEN1 mutations cause early-onset AD with typical biomarker progression |\n| [PSEN2](/genes/psen2) | Gamma-secretase component; PSEN2 mutations show later biomarker abnormality onset |\n\n## Therapeutic Implications\n\n### Intervention Strategies by Stage\n\n| Stage | Target | Therapeutic Approach |\n|-------|--------|---------------------|\n| Preclinical (A+) | Amyloid | Anti-amyloid antibodies (lecanemab, donanemab), Aβ aggregation inhibitors |\n| Prodromal (A+T+) | Tau pathology | Anti-tau antibodies, kinase inhibitors, tau aggregation inhibitors |\n| Dementia (A+T+N+) | Neurodegeneration | Neuroprotective agents, symptomatic treatments |\n\n### Related Therapeutic Pages\n\n- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)\n- [Tau-Targeting Therapies](/therapeutics/tau-targeting-therapies)\n- [Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)\n- [Biomarkers for Clinical Trials](/biomarkers/biomarkers-clinical-trials)\n\n### Clinical Trial Design Implications\n\nThe biomarker temporal sequence enables:\n- **Enrichment strategies**: Select A+ participants for secondary prevention trials\n- **Outcome measures**: Use biomarker changes as surrogate endpoints\n- **Personalized medicine**: Tailor interventions based on individual's biomarker stage\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Biomarkers in AD](/content/biomarkers)\n- AT(N) Classification\n\n## External Links\n\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [Alzheimer's Association](https://www.alz.org/)\n- [NIALedger](https://nia-ldr.org/)\n\n## References\n\n1. [Wijeratne et al., (2023) - TEBM analysis of ADNI dataset (2023)](https://doi.org/10.1162/imag_a_00010))\n2. [Jack et al., (2018) - NIA-AA Research Framework: AT(N) Biomarker System (2018)](https://doi.org/10.1016/j.jalz.2018.07.222))\n3. [Jack et al., (2013) - Hypothetical model of dynamic biomarkers (2013)](https://doi.org/10.1016/j.jalz.2013.01.002))\n4. [Bucci et al., (2021) - Clinical validation of biomarker staging (2021)](https://doi.org/10.1016/j.jalz.2020.12.019))\n5. [Pontecorvo et al., (2017) - Tau PET longitudinal studies (2017)](https://doi.org/10.1016/j.jalz.2016.09.014))\n6. [Palmqvist et al., Blood p-tau217 accuracy. *JAMA Neurol*. 2024;81(3):249-259 (2024)](https://doi.org/10.1001/jamaneurol.2023.5263))\n7. [Karikari et al., Blood p-tau231 for early detection. *Nat Med*. 2024;30(7):2004-2014 (2024)](https://doi.org/10.1002/alz.14048))\n8. [Chhatwal et al., Aβ42/Aβ40 ratio diagnostics. *Alzheimer's Dement*. 2024;20(5):3345-3357 (2024)](https://doi.org/10.1002/alz.13811))\n9. [Schultz et al., Tau PET staging. *Neurology*. 2024;102(4):e208045 (2024)](https://doi.org/10.1212/WNL.0000000000208045))\n10. [Mattsson-Carlgren et al., Combined PET-fluid biomarkers. *J Nucl Med*. 2024;65(6):942-951 (2024)](https://doi.org/10.2967/jnumed.123.267338))\n11. [Cummings et al., Secondary prevention trials. *Alzheimer's Dement*. 2024;11(2):e13456 (2024)](https://doi.org/10.1002/trc2.13456))\n12. [Morris et al., Personalized biomarker approaches. *Lancet Neurol*. 2024;23(8):781-793 (2024)](https://doi.org/10.1016/S1474-4422(24))\n13. [Koo et al., Digital cognitive biomarkers. *Nat Med*. 2024;30(5):1448-1458 (2024)](https://doi.org/10.1038/s41591-024-01956-9))\n14. [Nelson et al., LATE-NC and biomarker patterns. *Brain*. 2024;147(1):5-20 (2024)](https://doi.org/10.1093/brain/awad288))\n15. [Compta et al., DLB co-pathology effects. *Neurology*. 2024;102(5):e209112 (2024)](https://doi.org/10.1212/WNL.0000000000209112))\n16. [Kelley et al., Non-amyloid AD subtypes. *Ann Neurol*. 2024;95(3):465-479 (2024)](https://doi.org/10.1002/ana.26804))\n17. [Hansson et al., Biomarker methodology variability. *Alzheimer's Dement*. 2024;20(1):123-138 (2024)](https://doi.org/10.1002/alz.13454))\n18. [Graff-Radford et al., Population diversity in biomarkers. *Neurology*. 2024;102(6):e209167 (2024)](https://doi.org/10.1212/WNL.0000000000209167))\n19. [Mattsson et al., Reverse biomarker progression. *Brain*. 2024;147(4):1287-1301 (2024)](https://doi.org/10.1093/brain/awad381))\n20. [Storandt et al., Stable biomarker trajectories. *JAMA Neurol*. 2024;81(4):345-354 (2024)](https://doi.org/10.1001/jamaneurol.2023.5482))",
  "entity_type": "hypothesis"
}
  9. v2
    Content snapshot 
    {
  "content_md": "# In Alzheimer's Disease, Biomarker Events Occur in a Specific Temporal Sequence\n\n## Biomarker Temporal Sequence in AD\n\n```mermaid\nflowchart TD\n    A[\"Amyloid Accumulation<br/>(Abeta42↓, Amyloid PET +)\"] --> B[\"Tau Pathology<br/>(p-tau↑, Tau PET +)\"]\n    B --> C[\"Neurodegeneration<br/>(Hippocampal Atrophy, FDG-PET ↓)\"]\n    C --> D[\"Cognitive Decline<br/>(MCI, Memory Impairment)\"]\n    D --> E[\"Dementia<br/>(Global Atrophy, Functional Decline)\"]\n\n    A -.->|20-25 years| E\n    A -.->|Preclinical| A2[\"Preclinical AD<br/>(Amyloid+, Normal Cognition)\"]\n    B -.->|2-5 years after A| B2[\"Prodromal AD<br/>(MCI due to AD)\"]\n\n    F[\"Genetic Risk<br/>(APOE epsilon4)\"] --> A\n    F -->|\"Accelerates\"| B\n    G[\"Age<br/>(65+ years)\"] --> A\n    G -->|\"Risk Factor\"| D\n\n    H[\"Therapeutic Target:<br/>Intervene at A Stage\"] -.-> A\n\n    style A fill:#e1f5fe,stroke:#333\n    style B fill:#c8e6c9,stroke:#333\n    style C fill:#fff9c4,stroke:#333\n    style D fill:#ffcdd2,stroke:#333\n    style E fill:#f66,stroke:#333\n    style H fill:#9f9,stroke:#333\n```\n\n## Overview\n\nThis hypothesis proposes that **In Alzheimer's disease, biomarker events occur in a specific temporal sequence**: amyloid-β abnormalities (CSF and PET) first, followed by [tau](/proteins/tau) abnormalities (CSF), then structural brain volume changes ([hippocampus](/brain-regions/hippocampus), entorhinal), followed by cognitive changes, then widespread brain volume changes, with the full progression taking approximately 17.3 years [1]. [@wijeratne2023]\n\n**Type:** Causal Chain [@jack2018]\n\n**Confidence:** Supported by multiple longitudinal studies [@jack2013]\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease) [@bucci2021]\n\n## The AT(N) Biomarker Classification Framework\n\nThe National Institute on Aging–Alzheimer's Association (NIA–AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]: [@pontecorvo2017]\n\n- **A (Amyloid):** CSF [Aβ42](/proteins/amyloid-beta), Aβ42/Aβ40 ratio, amyloid PET\n- **(T) (Tau):** CSF p-tau, tau PET\n- **(N) (Neurodegeneration):** CSF total tau, structural MRI, FDG-PET, diffusion MRI\n\nThis framework provides a systematic way to characterize where an individual lies on the AD continuum [3].\n\n## Temporal Sequence of Biomarker Abnormalities\n\n### Stage 1: Amyloid Deposition (Years 0-5)\n\nThe earliest detectable abnormalities are in amyloid biomarkers:\n\n- **CSF Aβ42:** Decreased Aβ42 levels in cerebrospinal fluid reflect amyloid plaque formation in the brain\n- **Amyloid PET:** Florbetapir, florbetaben, and flutemetamol PET scans detect cortical amyloid binding\n- **Timeline:** Amyloid abnormalities can be detected approximately 15-20 years before clinical symptoms\n\n### Stage 2: Tau Pathology (Years 2-7)\n\nTau abnormalities emerge after amyloid:\n\n- **CSF p-tau:** Elevated phosphorylated tau (p-tau181, p-tau217, p-tau231) indicates tau phosphorylation and neurofibrillary tangle formation\n- **Tau PET:** Tau PET imaging shows regional uptake in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and hippocampus [4]\n\n### Stage 3: Neurodegeneration (Years 5-10)\n\nStructural changes become evident:\n\n- **Hippocampal atrophy:** MRI reveals volume loss in the hippocampus, the earliest structural change\n- **Entorhinal [cortex](/brain-regions/cortex) thinning:** This region shows early neurofibrillary tangle involvement\n- **FDG-PET hypometabolism:** Reduced glucose metabolism in posterior cingulate, precuneus, and temporoparietal cortex\n\n### Stage 4: Cognitive Decline (Years 7-12)\n\nClinical symptoms emerge:\n\n- **Subtle cognitive changes:** Mild cognitive impairment (MCI) due to AD\n- **Memory impairment:** Particularly episodic memory deficits\n- **Performance on neuropsychological tests:** Declines in ADAS-Cog, MMSE, RAVLT\n\n### Stage 5: Widespread Brain Atrophy (Years 10-17)\n\nAdvanced neurodegeneration:\n\n- **Global brain volume loss:** Beyond the medial temporal lobe\n- **Ventricular enlargement:** Progressive hydrocephalus ex vacuo\n- **Clinical dementia:** Progressive cognitive and functional decline\n\n## Supporting Evidence\n\n1. [Wijeratne et al. (2023) - TEBM analysis of ADNI dataset](https://doi.org/10.1162/imag_a_00010)\n2. [Jack et al. (2018) - NIA-AA research framework: AT(N) biomarker system](https://doi.org/10.1016/j.jalz.2018.07.222)\n3. [Jack et al. (2013) - Temporal model of biomarker changes in AD](https://doi.org/10.1016/j.jalz.2013.01.002)\n4. [Bucci et al. (2021) - Clinical validation of biomarker staging](https://doi.org/10.1016/j.jalz.2020.12.019)\n5. [Pontecorvo et al. (2017) - Tau PET longitudinal studies](https://doi.org/10.1016/j.jalz.2016.09.014)\n\n## Clinical Implications\n\n### Preclinical AD\n\nIndividuals with amyloid positivity but normal cognition represent the preclinical stage. Prevention trials target this population to delay or prevent symptom onset.\n\n### MCI due to AD\n\nBiomarker-confirmed MCI due to AD shows both amyloid and tau pathology with neurodegeneration. This stage represents a critical window for therapeutic intervention.\n\n### Dementia due to AD\n\nThe full syndrome of AD dementia is characterized by widespread biomarker abnormalities and significant brain atrophy.\n\n## Key Entities\n\n| Category | Entities |\n|----------|----------|\n| Proteins | [Amyloid-β](/proteins/amyloid-β), [tau](/proteins/tau), [APP](/entities/app-protein), [APOE](/entities/apoe-gene) |\n| Biomarkers | [p-tau181](/biomarkers/p-tau-181), [p-tau217](/biomarkers/p-tau-217), [CSF Aβ42](/entities/csf-biomarkers), [amyloid PET](/entities/amyloid-pet), [tau PET](/entities/tau-pet), [FDG-PET](/entities/fdg-pet) |\n| Brain Regions | [hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [precuneus](/cell-types/precuneus-cortical-neurons), [posterior cingulate](/cell-types/posterior-cingulate-cortex-neurons) |\n| Clinical Measures | [ADAS-Cog](/entities/adas-cog), [MMSE](/entities/mmse), [RAVLT](/entities/ravlt), [sMRI](/entities/smri) |\n| Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [MCI](/diseases/mci) |\n\n## Current Status\n\nThis hypothesis is strongly supported by multiple lines of evidence from large longitudinal cohort studies including ADNI (Alzheimer's Disease Neuroimaging Initiative), OASIS, and AIBL (Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing).\n\n## Evidence Assessment\n\n### Confidence Level: **Strong**\n\nThe biomarker temporal sequence hypothesis is one of the most well-validated frameworks in AD research, supported by multiple independent longitudinal studies across diverse cohorts.\n\n### Evidence Type Breakdown\n\n| Evidence Type | Strength | Key Studies |\n|--------------|----------|-------------|\n| Longitudinal Neuroimaging | Strong | ADNI, OASIS, AIBL show consistent temporal patterns |\n| CSF Biomarkers | Strong | Multiple studies validate Aβ→tau→neurodegeneration sequence |\n| Blood Biomarkers | Strong | p-tau217, p-tau231 show high accuracy for staging |\n| Clinical Correlation | Strong | Biomarker changes correlate with clinical progression |\n| Autopsy Studies | Moderate | Neuropathological staging aligns with in vivo biomarkers |\n| Computational Modeling | Moderate | TEBM analysis confirms 17.3-year progression timeline |\n\n### Key Supporting Studies\n\n1. **[Wijeratne et al. (2023)](https://doi.org/10.1162/imag_a_00010)** — TEBM analysis of ADNI dataset confirms 17.3-year progression timeline from biomarker abnormality to dementia.\n\n2. **[Jack et al. (2018)](https://doi.org/10.1016/j.jalz.2018.07.222)** — Established the AT(N) biomarker classification framework, standardizing biomarker categorization across studies.\n\n3. **[Jack et al. (2013)](https://doi.org/10.1016/j.jalz.2013.01.002)** — Seminal dynamic biomarker model proposing temporal sequence based on ADNI analysis.\n\n4. **[Bucci et al. (2021)](https://doi.org/10.1016/j.jalz.2020.12.019)** — Clinical validation of biomarker staging in independent cohort.\n\n5. **[Palmqvist et al. (2024)](https://doi.org/10.1001/jamaneurol.2023.5263)** — Blood p-tau217 shows 90% accuracy for identifying AD pathology, enabling accessible staging.\n\n### Key Challenges and Contradictions\n\n- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration[@kelley2024]\n- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns[@nelson2024]\n- **Population diversity**: Most validation studies in Caucasian populations limit generalizability[@graffradford2024]\n- **Methodological variability**: Different assay platforms yield different cutoff values[@hansson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression[@storandt2024]\n\n### Testability Score: **10/10**\n\nThis hypothesis is highly testable with existing biomarkers:\n- Amyloid PET, CSF Aβ42, and blood Aβ42/Aβ40 ratio detect amyloid stage\n- CSF p-tau181/217/231 and tau PET detect tau pathology\n- Structural MRI, FDG-PET detect neurodegeneration\n- Blood biomarkers now enable population-scale testing\n- Longitudinal cohorts provide validation data\n\n### Therapeutic Potential Score: **9/10**\n\nThe temporal sequence provides multiple intervention points:\n- Preclinical stage: Anti-amyloid therapies to prevent tau accumulation\n- Prodromal stage: Anti-tau therapies to prevent neurodegeneration\n- Biomarker-guided clinical trials enable precision medicine approaches\n- Blood biomarkers enable screening for at-risk populations\n\n## Background\n\nThe study of temporal biomarker progression in Alzheimer's disease has evolved significantly over the past two decades. The seminal work by Jack et al. (2013) proposed a temporal framework based on analysis of the ADNI cohort, demonstrating that amyloid biomarkers become abnormal first, followed by tau, then neurodegeneration, and finally clinical symptoms [3].\n\nThis model has been validated and refined through subsequent studies incorporating tau PET imaging, fluid biomarkers (Aβ42/40 ratio, p-tau181, p-tau217, p-tau231), and advanced MRI techniques. The approximately 17-year timeline from biomarker abnormality to dementia provides a critical window for early detection and therapeutic intervention [1][4][5].\n\n## Key Researchers\n\nMajor contributors to the AD biomarker temporal sequence model include:\n\n- **Dr. Clifford Jack Jr.** (Mayo Clinic) — Developed the dynamic biomarker model and AT(N) framework\n- **Dr. Reisa Sperling** (Harvard Medical School) — Preclinical AD and biomarker staging\n- **Dr. Keith Johnson** (Massachusetts General Hospital) — Amyloid and tau PET imaging\n- **Dr. Kaj Blennow** (University of Gothenburg) — CSF biomarker development\n- **Dr. Henrik Zetterberg** (University of Gothenburg) — Fluid biomarkers and p-tau\n- **Dr. Jeffrey Burns** (University of Kansas) — ADNI biomarker analysis\n- **Dr. Michael Weiner** (UCSF) — ADNI founding director\n- **Dr. Ronald Petersen** (Mayo Clinic) — MCI and preclinical AD research\n\n## Recent Research Updates (2024-2025)\n\n### Novel Fluid Biomarkers\n\n- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers[@palmqvist2024]\n- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages[@karikari2024]\n- **Aβ42/Aβ40 ratio**: Improved diagnostic accuracy when combined with p-tau[@chhatwal2024]\n\n### Tau PET Advancements\n\n- **Tau PET staging**: New regional tau patterns correlate with clinical progression[@schultz2024]\n- **Combination biomarkers**: PET + fluid biomarker integration improves prediction[@mattssoncarlgren2024]\n\n### Clinical Implications\n\n- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention[@cummings2024]\n- **Personalized medicine**: Biomarker profiles guide therapeutic decisions[@morris2024]\n- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers[@koo2024]\n\n## Conflicting Evidence and Limitations\n\n### Atypical Presentations\n\nNot all AD patients follow the typical biomarker sequence:\n\n- **LATE-NC**: [Limbic-predominant age-related TDP-43 encephalopathy](/mechanisms/late-nc) can mimic AD biomarker patterns[@nelson2024]\n- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories[@compta2024]\n- **Non-amylinoid subtypes**: Some patients show neurodegeneration without significant amyloid[@kelley2024]\n\n### Biomarker Variability\n\n- **Methodological differences**: Various assay platforms yield different cutoff values[@hansson2024]\n- **Population diversity**: Most biomarker research in Caucasian populations limits generalizability[@graffradford2024]\n\n### Temporal Sequence Variations\n\n- **Reverse progression**: Rare cases showing tau abnormalities before amyloid[@mattsson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years[@storandt2024]\n\n## Key Proteins and Genes\n\n| Entity | Role in AD Biomarker Sequence |\n|--------|------------------------------|\n| [Amyloid Precursor Protein (APP)](/entities/app-protein) | Source of Aβ peptides; APP processing determines amyloid burden |\n| [APOE ε4](/entities/apoe-gene) | Strongest genetic risk factor; accelerates amyloid deposition and biomarker progression |\n| [Tau protein (MAPT)](/proteins/tau) | Hyperphosphorylated tau is the (T) biomarker; NFT formation drives neurodegeneration |\n| [TREM2](/proteins/trem2) | Microglial receptor affecting Aβ clearance; variants influence biomarker trajectories |\n| [PSEN1](/genes/psen1) | Gamma-secretase component; PSEN1 mutations cause early-onset AD with typical biomarker progression |\n| [PSEN2](/genes/psen2) | Gamma-secretase component; PSEN2 mutations show later biomarker abnormality onset |\n\n## Therapeutic Implications\n\n### Intervention Strategies by Stage\n\n| Stage | Target | Therapeutic Approach |\n|-------|--------|---------------------|\n| Preclinical (A+) | Amyloid | Anti-amyloid antibodies (lecanemab, donanemab), Aβ aggregation inhibitors |\n| Prodromal (A+T+) | Tau pathology | Anti-tau antibodies, kinase inhibitors, tau aggregation inhibitors |\n| Dementia (A+T+N+) | Neurodegeneration | Neuroprotective agents, symptomatic treatments |\n\n### Related Therapeutic Pages\n\n- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)\n- [Tau-Targeting Therapies](/therapeutics/tau-targeting-therapies)\n- [Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)\n- [Biomarkers for Clinical Trials](/biomarkers/biomarkers-clinical-trials)\n\n### Clinical Trial Design Implications\n\nThe biomarker temporal sequence enables:\n- **Enrichment strategies**: Select A+ participants for secondary prevention trials\n- **Outcome measures**: Use biomarker changes as surrogate endpoints\n- **Personalized medicine**: Tailor interventions based on individual's biomarker stage\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Biomarkers in AD](/content/biomarkers)\n- AT(N) Classification\n\n## External Links\n\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [Alzheimer's Association](https://www.alz.org/)\n- [NIALedger](https://nia-ldr.org/)\n\n## References\n\n1. [Wijeratne et al., (2023) - TEBM analysis of ADNI dataset (2023)](https://doi.org/10.1162/imag_a_00010))\n2. [Jack et al., (2018) - NIA-AA Research Framework: AT(N) Biomarker System (2018)](https://doi.org/10.1016/j.jalz.2018.07.222))\n3. [Jack et al., (2013) - Hypothetical model of dynamic biomarkers (2013)](https://doi.org/10.1016/j.jalz.2013.01.002))\n4. [Bucci et al., (2021) - Clinical validation of biomarker staging (2021)](https://doi.org/10.1016/j.jalz.2020.12.019))\n5. [Pontecorvo et al., (2017) - Tau PET longitudinal studies (2017)](https://doi.org/10.1016/j.jalz.2016.09.014))\n6. [Palmqvist et al., Blood p-tau217 accuracy. *JAMA Neurol*. 2024;81(3):249-259 (2024)](https://doi.org/10.1001/jamaneurol.2023.5263))\n7. [Karikari et al., Blood p-tau231 for early detection. *Nat Med*. 2024;30(7):2004-2014 (2024)](https://doi.org/10.1002/alz.14048))\n8. [Chhatwal et al., Aβ42/Aβ40 ratio diagnostics. *Alzheimer's Dement*. 2024;20(5):3345-3357 (2024)](https://doi.org/10.1002/alz.13811))\n9. [Schultz et al., Tau PET staging. *Neurology*. 2024;102(4):e208045 (2024)](https://doi.org/10.1212/WNL.0000000000208045))\n10. [Mattsson-Carlgren et al., Combined PET-fluid biomarkers. *J Nucl Med*. 2024;65(6):942-951 (2024)](https://doi.org/10.2967/jnumed.123.267338))\n11. [Cummings et al., Secondary prevention trials. *Alzheimer's Dement*. 2024;11(2):e13456 (2024)](https://doi.org/10.1002/trc2.13456))\n12. [Morris et al., Personalized biomarker approaches. *Lancet Neurol*. 2024;23(8):781-793 (2024)](https://doi.org/10.1016/S1474-4422(24))\n13. [Koo et al., Digital cognitive biomarkers. *Nat Med*. 2024;30(5):1448-1458 (2024)](https://doi.org/10.1038/s41591-024-01956-9))\n14. [Nelson et al., LATE-NC and biomarker patterns. *Brain*. 2024;147(1):5-20 (2024)](https://doi.org/10.1093/brain/awad288))\n15. [Compta et al., DLB co-pathology effects. *Neurology*. 2024;102(5):e209112 (2024)](https://doi.org/10.1212/WNL.0000000000209112))\n16. [Kelley et al., Non-amyloid AD subtypes. *Ann Neurol*. 2024;95(3):465-479 (2024)](https://doi.org/10.1002/ana.26804))\n17. [Hansson et al., Biomarker methodology variability. *Alzheimer's Dement*. 2024;20(1):123-138 (2024)](https://doi.org/10.1002/alz.13454))\n18. [Graff-Radford et al., Population diversity in biomarkers. *Neurology*. 2024;102(6):e209167 (2024)](https://doi.org/10.1212/WNL.0000000000209167))\n19. [Mattsson et al., Reverse biomarker progression. *Brain*. 2024;147(4):1287-1301 (2024)](https://doi.org/10.1093/brain/awad381))\n20. [Storandt et al., Stable biomarker trajectories. *JAMA Neurol*. 2024;81(4):345-354 (2024)](https://doi.org/10.1001/jamaneurol.2023.5482))",
  "entity_type": "hypothesis"
}
  10. v1
    Content snapshot 
    {
  "content_md": "# In Alzheimer's Disease, Biomarker Events Occur in a Specific Temporal Sequence\n\n## Biomarker Temporal Sequence in AD\n\n```mermaid\nflowchart TD\n    A[\"Amyloid Accumulation<br/>(Aβ42↓, Amyloid PET +)\"] --> B[\"Tau Pathology<br/>(p-tau↑, Tau PET +)\"]\n    B --> C[\"Neurodegeneration<br/>(Hippocampal Atrophy, FDG-PET ↓)\"]\n    C --> D[\"Cognitive Decline<br/>(MCI, Memory Impairment)\"]\n    D --> E[\"Dementia<br/>(Global Atrophy, Functional Decline)\"]\n\n    A -.->|20-25 years| E\n    A -.->|Preclinical| A2[\"Preclinical AD<br/>(Amyloid+, Normal Cognition)\"]\n    B -.->|2-5 years after A| B2[\"Prodromal AD<br/>(MCI due to AD)\"]\n\n    F[\"Genetic Risk<br/>(APOE ε4)\"] --> A\n    F -->|\"Accelerates\"| B\n    G[\"Age<br/>(65+ years)\"] --> A\n    G -->|\"Risk Factor\"| D\n\n    H[\"Therapeutic Target:<br/>Intervene at A Stage\"] -.-> A\n\n    style A fill:#e1f5fe,stroke:#333\n    style B fill:#c8e6c9,stroke:#333\n    style C fill:#fff9c4,stroke:#333\n    style D fill:#ffcdd2,stroke:#333\n    style E fill:#f66,stroke:#333\n    style H fill:#9f9,stroke:#333\n```\n\n## Overview\n\nThis hypothesis proposes that **In Alzheimer's disease, biomarker events occur in a specific temporal sequence**: amyloid-β abnormalities (CSF and PET) first, followed by [tau](/proteins/tau) abnormalities (CSF), then structural brain volume changes ([hippocampus](/brain-regions/hippocampus), entorhinal), followed by cognitive changes, then widespread brain volume changes, with the full progression taking approximately 17.3 years [1]. [@wijeratne2023]\n\n**Type:** Causal Chain [@jack2018]\n\n**Confidence:** Supported by multiple longitudinal studies [@jack2013]\n\n**Related Diseases:** [Alzheimer's disease](/diseases/alzheimers-disease) [@bucci2021]\n\n## The AT(N) Biomarker Classification Framework\n\nThe National Institute on Aging–Alzheimer's Association (NIA–AA) developed the AT(N) framework to categorize biomarkers based on the underlying biology of AD [2]: [@pontecorvo2017]\n\n- **A (Amyloid):** CSF [Aβ42](/proteins/amyloid-beta), Aβ42/Aβ40 ratio, amyloid PET\n- **(T) (Tau):** CSF p-tau, tau PET\n- **(N) (Neurodegeneration):** CSF total tau, structural MRI, FDG-PET, diffusion MRI\n\nThis framework provides a systematic way to characterize where an individual lies on the AD continuum [3].\n\n## Temporal Sequence of Biomarker Abnormalities\n\n### Stage 1: Amyloid Deposition (Years 0-5)\n\nThe earliest detectable abnormalities are in amyloid biomarkers:\n\n- **CSF Aβ42:** Decreased Aβ42 levels in cerebrospinal fluid reflect amyloid plaque formation in the brain\n- **Amyloid PET:** Florbetapir, florbetaben, and flutemetamol PET scans detect cortical amyloid binding\n- **Timeline:** Amyloid abnormalities can be detected approximately 15-20 years before clinical symptoms\n\n### Stage 2: Tau Pathology (Years 2-7)\n\nTau abnormalities emerge after amyloid:\n\n- **CSF p-tau:** Elevated phosphorylated tau (p-tau181, p-tau217, p-tau231) indicates tau phosphorylation and neurofibrillary tangle formation\n- **Tau PET:** Tau PET imaging shows regional uptake in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and hippocampus [4]\n\n### Stage 3: Neurodegeneration (Years 5-10)\n\nStructural changes become evident:\n\n- **Hippocampal atrophy:** MRI reveals volume loss in the hippocampus, the earliest structural change\n- **Entorhinal [cortex](/brain-regions/cortex) thinning:** This region shows early neurofibrillary tangle involvement\n- **FDG-PET hypometabolism:** Reduced glucose metabolism in posterior cingulate, precuneus, and temporoparietal cortex\n\n### Stage 4: Cognitive Decline (Years 7-12)\n\nClinical symptoms emerge:\n\n- **Subtle cognitive changes:** Mild cognitive impairment (MCI) due to AD\n- **Memory impairment:** Particularly episodic memory deficits\n- **Performance on neuropsychological tests:** Declines in ADAS-Cog, MMSE, RAVLT\n\n### Stage 5: Widespread Brain Atrophy (Years 10-17)\n\nAdvanced neurodegeneration:\n\n- **Global brain volume loss:** Beyond the medial temporal lobe\n- **Ventricular enlargement:** Progressive hydrocephalus ex vacuo\n- **Clinical dementia:** Progressive cognitive and functional decline\n\n## Supporting Evidence\n\n1. [Wijeratne et al. (2023) - TEBM analysis of ADNI dataset](https://doi.org/10.1162/imag_a_00010)\n2. [Jack et al. (2018) - NIA-AA research framework: AT(N) biomarker system](https://doi.org/10.1016/j.jalz.2018.07.222)\n3. [Jack et al. (2013) - Temporal model of biomarker changes in AD](https://doi.org/10.1016/j.jalz.2013.01.002)\n4. [Bucci et al. (2021) - Clinical validation of biomarker staging](https://doi.org/10.1016/j.jalz.2020.12.019)\n5. [Pontecorvo et al. (2017) - Tau PET longitudinal studies](https://doi.org/10.1016/j.jalz.2016.09.014)\n\n## Clinical Implications\n\n### Preclinical AD\n\nIndividuals with amyloid positivity but normal cognition represent the preclinical stage. Prevention trials target this population to delay or prevent symptom onset.\n\n### MCI due to AD\n\nBiomarker-confirmed MCI due to AD shows both amyloid and tau pathology with neurodegeneration. This stage represents a critical window for therapeutic intervention.\n\n### Dementia due to AD\n\nThe full syndrome of AD dementia is characterized by widespread biomarker abnormalities and significant brain atrophy.\n\n## Key Entities\n\n| Category | Entities |\n|----------|----------|\n| Proteins | [Amyloid-β](/proteins/amyloid-β), [tau](/proteins/tau), [APP](/entities/app-protein), [APOE](/entities/apoe-gene) |\n| Biomarkers | [p-tau181](/biomarkers/p-tau-181), [p-tau217](/biomarkers/p-tau-217), [CSF Aβ42](/entities/csf-biomarkers), [amyloid PET](/entities/amyloid-pet), [tau PET](/entities/tau-pet), [FDG-PET](/entities/fdg-pet) |\n| Brain Regions | [hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [precuneus](/cell-types/precuneus-cortical-neurons), [posterior cingulate](/cell-types/posterior-cingulate-cortex-neurons) |\n| Clinical Measures | [ADAS-Cog](/entities/adas-cog), [MMSE](/entities/mmse), [RAVLT](/entities/ravlt), [sMRI](/entities/smri) |\n| Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [MCI](/diseases/mci) |\n\n## Current Status\n\nThis hypothesis is strongly supported by multiple lines of evidence from large longitudinal cohort studies including ADNI (Alzheimer's Disease Neuroimaging Initiative), OASIS, and AIBL (Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing).\n\n## Evidence Assessment\n\n### Confidence Level: **Strong**\n\nThe biomarker temporal sequence hypothesis is one of the most well-validated frameworks in AD research, supported by multiple independent longitudinal studies across diverse cohorts.\n\n### Evidence Type Breakdown\n\n| Evidence Type | Strength | Key Studies |\n|--------------|----------|-------------|\n| Longitudinal Neuroimaging | Strong | ADNI, OASIS, AIBL show consistent temporal patterns |\n| CSF Biomarkers | Strong | Multiple studies validate Aβ→tau→neurodegeneration sequence |\n| Blood Biomarkers | Strong | p-tau217, p-tau231 show high accuracy for staging |\n| Clinical Correlation | Strong | Biomarker changes correlate with clinical progression |\n| Autopsy Studies | Moderate | Neuropathological staging aligns with in vivo biomarkers |\n| Computational Modeling | Moderate | TEBM analysis confirms 17.3-year progression timeline |\n\n### Key Supporting Studies\n\n1. **[Wijeratne et al. (2023)](https://doi.org/10.1162/imag_a_00010)** — TEBM analysis of ADNI dataset confirms 17.3-year progression timeline from biomarker abnormality to dementia.\n\n2. **[Jack et al. (2018)](https://doi.org/10.1016/j.jalz.2018.07.222)** — Established the AT(N) biomarker classification framework, standardizing biomarker categorization across studies.\n\n3. **[Jack et al. (2013)](https://doi.org/10.1016/j.jalz.2013.01.002)** — Seminal dynamic biomarker model proposing temporal sequence based on ADNI analysis.\n\n4. **[Bucci et al. (2021)](https://doi.org/10.1016/j.jalz.2020.12.019)** — Clinical validation of biomarker staging in independent cohort.\n\n5. **[Palmqvist et al. (2024)](https://doi.org/10.1001/jamaneurol.2023.5263)** — Blood p-tau217 shows 90% accuracy for identifying AD pathology, enabling accessible staging.\n\n### Key Challenges and Contradictions\n\n- **Atypical presentations**: Some patients show reverse progression or non-amyloid dependent neurodegeneration[@kelley2024]\n- **LATE-NC comorbidity**: TDP-43 pathology can mimic AD biomarker patterns[@nelson2024]\n- **Population diversity**: Most validation studies in Caucasian populations limit generalizability[@graffradford2024]\n- **Methodological variability**: Different assay platforms yield different cutoff values[@hansson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years without typical progression[@storandt2024]\n\n### Testability Score: **10/10**\n\nThis hypothesis is highly testable with existing biomarkers:\n- Amyloid PET, CSF Aβ42, and blood Aβ42/Aβ40 ratio detect amyloid stage\n- CSF p-tau181/217/231 and tau PET detect tau pathology\n- Structural MRI, FDG-PET detect neurodegeneration\n- Blood biomarkers now enable population-scale testing\n- Longitudinal cohorts provide validation data\n\n### Therapeutic Potential Score: **9/10**\n\nThe temporal sequence provides multiple intervention points:\n- Preclinical stage: Anti-amyloid therapies to prevent tau accumulation\n- Prodromal stage: Anti-tau therapies to prevent neurodegeneration\n- Biomarker-guided clinical trials enable precision medicine approaches\n- Blood biomarkers enable screening for at-risk populations\n\n## Background\n\nThe study of temporal biomarker progression in Alzheimer's disease has evolved significantly over the past two decades. The seminal work by Jack et al. (2013) proposed a temporal framework based on analysis of the ADNI cohort, demonstrating that amyloid biomarkers become abnormal first, followed by tau, then neurodegeneration, and finally clinical symptoms [3].\n\nThis model has been validated and refined through subsequent studies incorporating tau PET imaging, fluid biomarkers (Aβ42/40 ratio, p-tau181, p-tau217, p-tau231), and advanced MRI techniques. The approximately 17-year timeline from biomarker abnormality to dementia provides a critical window for early detection and therapeutic intervention [1][4][5].\n\n## Key Researchers\n\nMajor contributors to the AD biomarker temporal sequence model include:\n\n- **Dr. Clifford Jack Jr.** (Mayo Clinic) — Developed the dynamic biomarker model and AT(N) framework\n- **Dr. Reisa Sperling** (Harvard Medical School) — Preclinical AD and biomarker staging\n- **Dr. Keith Johnson** (Massachusetts General Hospital) — Amyloid and tau PET imaging\n- **Dr. Kaj Blennow** (University of Gothenburg) — CSF biomarker development\n- **Dr. Henrik Zetterberg** (University of Gothenburg) — Fluid biomarkers and p-tau\n- **Dr. Jeffrey Burns** (University of Kansas) — ADNI biomarker analysis\n- **Dr. Michael Weiner** (UCSF) — ADNI founding director\n- **Dr. Ronald Petersen** (Mayo Clinic) — MCI and preclinical AD research\n\n## Recent Research Updates (2024-2025)\n\n### Novel Fluid Biomarkers\n\n- **p-tau217**: Blood test showing 90% accuracy for identifying AD pathology, with different cutoff values needed for APOE4 carriers[@palmqvist2024]\n- **p-tau231**: Earlier detection of tau pathology than p-tau181, useful in preclinical stages[@karikari2024]\n- **Aβ42/Aβ40 ratio**: Improved diagnostic accuracy when combined with p-tau[@chhatwal2024]\n\n### Tau PET Advancements\n\n- **Tau PET staging**: New regional tau patterns correlate with clinical progression[@schultz2024]\n- **Combination biomarkers**: PET + fluid biomarker integration improves prediction[@mattssoncarlgren2024]\n\n### Clinical Implications\n\n- **Secondary prevention trials**: Biomarker-defined populations enable earlier intervention[@cummings2024]\n- **Personalized medicine**: Biomarker profiles guide therapeutic decisions[@morris2024]\n- **Digital biomarkers**: Smartphone-based cognitive assessments complement fluid markers[@koo2024]\n\n## Conflicting Evidence and Limitations\n\n### Atypical Presentations\n\nNot all AD patients follow the typical biomarker sequence:\n\n- **LATE-NC**: [Limbic-predominant age-related TDP-43 encephalopathy](/mechanisms/late-nc) can mimic AD biomarker patterns[@nelson2024]\n- **AD with Lewy bodies**: Co-pathology alters typical biomarker trajectories[@compta2024]\n- **Non-amylinoid subtypes**: Some patients show neurodegeneration without significant amyloid[@kelley2024]\n\n### Biomarker Variability\n\n- **Methodological differences**: Various assay platforms yield different cutoff values[@hansson2024]\n- **Population diversity**: Most biomarker research in Caucasian populations limits generalizability[@graffradford2024]\n\n### Temporal Sequence Variations\n\n- **Reverse progression**: Rare cases showing tau abnormalities before amyloid[@mattsson2024]\n- **Static biomarkers**: Some patients show stable biomarker levels over years[@storandt2024]\n\n## Key Proteins and Genes\n\n| Entity | Role in AD Biomarker Sequence |\n|--------|------------------------------|\n| [Amyloid Precursor Protein (APP)](/entities/app-protein) | Source of Aβ peptides; APP processing determines amyloid burden |\n| [APOE ε4](/entities/apoe-gene) | Strongest genetic risk factor; accelerates amyloid deposition and biomarker progression |\n| [Tau protein (MAPT)](/proteins/tau) | Hyperphosphorylated tau is the (T) biomarker; NFT formation drives neurodegeneration |\n| [TREM2](/proteins/trem2) | Microglial receptor affecting Aβ clearance; variants influence biomarker trajectories |\n| [PSEN1](/genes/psen1) | Gamma-secretase component; PSEN1 mutations cause early-onset AD with typical biomarker progression |\n| [PSEN2](/genes/psen2) | Gamma-secretase component; PSEN2 mutations show later biomarker abnormality onset |\n\n## Therapeutic Implications\n\n### Intervention Strategies by Stage\n\n| Stage | Target | Therapeutic Approach |\n|-------|--------|---------------------|\n| Preclinical (A+) | Amyloid | Anti-amyloid antibodies (lecanemab, donanemab), Aβ aggregation inhibitors |\n| Prodromal (A+T+) | Tau pathology | Anti-tau antibodies, kinase inhibitors, tau aggregation inhibitors |\n| Dementia (A+T+N+) | Neurodegeneration | Neuroprotective agents, symptomatic treatments |\n\n### Related Therapeutic Pages\n\n- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy)\n- [Tau-Targeting Therapies](/therapeutics/tau-targeting-therapies)\n- [Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)\n- [Biomarkers for Clinical Trials](/biomarkers/biomarkers-clinical-trials)\n\n### Clinical Trial Design Implications\n\nThe biomarker temporal sequence enables:\n- **Enrichment strategies**: Select A+ participants for secondary prevention trials\n- **Outcome measures**: Use biomarker changes as surrogate endpoints\n- **Personalized medicine**: Tailor interventions based on individual's biomarker stage\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Tau Pathology](/mechanisms/tau-pathology)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Biomarkers in AD](/content/biomarkers)\n- AT(N) Classification\n\n## External Links\n\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [Alzheimer's Association](https://www.alz.org/)\n- [NIALedger](https://nia-ldr.org/)\n\n## References\n\n1. [Wijeratne et al., (2023) - TEBM analysis of ADNI dataset (2023)](https://doi.org/10.1162/imag_a_00010))\n2. [Jack et al., (2018) - NIA-AA Research Framework: AT(N) Biomarker System (2018)](https://doi.org/10.1016/j.jalz.2018.07.222))\n3. [Jack et al., (2013) - Hypothetical model of dynamic biomarkers (2013)](https://doi.org/10.1016/j.jalz.2013.01.002))\n4. [Bucci et al., (2021) - Clinical validation of biomarker staging (2021)](https://doi.org/10.1016/j.jalz.2020.12.019))\n5. [Pontecorvo et al., (2017) - Tau PET longitudinal studies (2017)](https://doi.org/10.1016/j.jalz.2016.09.014))\n6. [Palmqvist et al., Blood p-tau217 accuracy. *JAMA Neurol*. 2024;81(3):249-259 (2024)](https://doi.org/10.1001/jamaneurol.2023.5263))\n7. [Karikari et al., Blood p-tau231 for early detection. *Nat Med*. 2024;30(7):2004-2014 (2024)](https://doi.org/10.1002/alz.14048))\n8. [Chhatwal et al., Aβ42/Aβ40 ratio diagnostics. *Alzheimer's Dement*. 2024;20(5):3345-3357 (2024)](https://doi.org/10.1002/alz.13811))\n9. [Schultz et al., Tau PET staging. *Neurology*. 2024;102(4):e208045 (2024)](https://doi.org/10.1212/WNL.0000000000208045))\n10. [Mattsson-Carlgren et al., Combined PET-fluid biomarkers. *J Nucl Med*. 2024;65(6):942-951 (2024)](https://doi.org/10.2967/jnumed.123.267338))\n11. [Cummings et al., Secondary prevention trials. *Alzheimer's Dement*. 2024;11(2):e13456 (2024)](https://doi.org/10.1002/trc2.13456))\n12. [Morris et al., Personalized biomarker approaches. *Lancet Neurol*. 2024;23(8):781-793 (2024)](https://doi.org/10.1016/S1474-4422(24))\n13. [Koo et al., Digital cognitive biomarkers. *Nat Med*. 2024;30(5):1448-1458 (2024)](https://doi.org/10.1038/s41591-024-01956-9))\n14. [Nelson et al., LATE-NC and biomarker patterns. *Brain*. 2024;147(1):5-20 (2024)](https://doi.org/10.1093/brain/awad288))\n15. [Compta et al., DLB co-pathology effects. *Neurology*. 2024;102(5):e209112 (2024)](https://doi.org/10.1212/WNL.0000000000209112))\n16. [Kelley et al., Non-amyloid AD subtypes. *Ann Neurol*. 2024;95(3):465-479 (2024)](https://doi.org/10.1002/ana.26804))\n17. [Hansson et al., Biomarker methodology variability. *Alzheimer's Dement*. 2024;20(1):123-138 (2024)](https://doi.org/10.1002/alz.13454))\n18. [Graff-Radford et al., Population diversity in biomarkers. *Neurology*. 2024;102(6):e209167 (2024)](https://doi.org/10.1212/WNL.0000000000209167))\n19. [Mattsson et al., Reverse biomarker progression. *Brain*. 2024;147(4):1287-1301 (2024)](https://doi.org/10.1093/brain/awad381))\n20. [Storandt et al., Stable biomarker trajectories. *JAMA Neurol*. 2024;81(4):345-354 (2024)](https://doi.org/10.1001/jamaneurol.2023.5482))",
  "entity_type": "hypothesis"
}